Methods for treating inflammatory skin conditions
Patent Information
- Application Number
- JP2023533727
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-17
- Filing Date
- 2021-12-03
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for inflammatory skin conditions such as atopic dermatitis and allergic contact dermatitis are inadequate for moderate to severe cases and come with significant adverse side effects, highlighting the need for new interventions that target underlying immunological pathways.
Development of a method using compounds that neutralize signaling by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-5 (IL-5) through antibodies or proteins that bind to CD131, reducing inflammatory cell accumulation and inflammation in inflammatory skin conditions.
The method effectively reduces swelling, mast cell infiltration, neutrophil infiltration, and CD8+ T cell infiltration at the site of inflammation, providing a potential treatment for a wide range of inflammatory skin conditions, including atopic dermatitis and allergic contact dermatitis, with reduced side effects.
Abstract
Description
[Technical Field]
[0001] Related application data This application claims priority to Australian Patent Application No. 2020 / 904494, entitled “Methods for treating inflammatory skin conditions,” filed on 4 December 2020, and Australian Patent Application No. 2021 / 901818, entitled “Methods for treating inflammatory skin conditions,” filed on 17 June 2021. The entire contents of both applications are incorporated herein by reference.
[0002] Sequence List This application is filed together with an electronic sequence listing. The entire contents of the sequence listing are incorporated herein by reference.
[0003] This disclosure relates to a method for treating the inflammatory skin condition in question. [Background technology]
[0004] Inflammatory skin conditions such as atopic dermatitis (AD) and allergic contact dermatitis (ACD) affect a large portion of the general population. For example, AD affects 10-15% of children, and ACD affects 15-20% of the general population worldwide. Many patients carry these inflammatory skin conditions into adulthood, making the disease lifelong for some. Therefore, developing effective treatments for these conditions would represent a significant advance in public health.
[0005] The underlying causes of inflammatory skin conditions include a combination of genetic and environmental factors, and several overlapping immunological pathways are thought to contribute to the development of the disease. Due to the multifactorial nature of inflammatory skin conditions, the effectiveness of currently available drugs is limited. The mainstay of treatment has been topical therapies, including emollients, corticosteroids, and calcineurin inhibitors, for mild cases. However, these therapies are insufficient for recalcitrant inflammation in patients with moderate to severe disease and are known to cause substantial adverse side effects. Despite insufficient evidence, the use of systemic corticosteroids in combination with antihistamines or prolonged phototherapy may be used. Patients with severe disease refractory to conventional treatments may be treated with systemic nonsteroidal anti-steroid (NSAID) therapies, which have varying levels of evidence, including cyclosporine A, methotrexate, azathioprine, and mycophenolate mofetil. Such drugs are nonspecific immunosuppressants, each with its own undesirable side effects.
[0006] Therefore, there is a need for new interventions to treat inflammatory skin conditions. [Overview of the Initiative]
[0007] In developing this invention, the inventors developed a transgenic mouse model of ACD. The transgenic mouse expresses human CD131(βc) and is useful for investigating the effects of targeting human CD131. Using an antibody that binds to CD131, the inventors found that inhibiting granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL) 5 signaling reduced the accumulation of inflammatory cells and improved the disease. These findings provide a basis for methods of treating inflammatory skin conditions such as ACD.
[0008] Accordingly, in one example, the present disclosure provides a method for treating an inflammatory skin condition in a subject, the method comprising administering one or more compounds that neutralize GM-CSF and IL-5 signaling to the subject. Similarly, the present disclosure provides one or more compounds that neutralize GM-CSF and IL-5 signaling for use in treating an inflammatory skin condition in a subject. The present disclosure also provides the use of one or more compounds that neutralize GM-CSF and IL-5 signaling in the manufacture of a pharmaceutical product for treating an inflammatory skin condition.
[0009] In another example, the present disclosure provides a method for treating an inflammatory skin condition in a subject, the method comprising administering a compound to the subject that binds to CD131 and neutralizes GM-CSF and IL-5 signaling.
[0010] This disclosure also provides compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling for use in the treatment of inflammatory skin conditions in subjects. This disclosure also provides the use of compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling in the manufacture of pharmaceuticals for the treatment of inflammatory skin conditions.
[0011] The methods of the present disclosure are suitable for the treatment of any type of inflammatory skin condition, particularly those related to GM-CSF and / or IL-5 signaling. In some examples, inflammatory skin conditions include hypersensitivity, autoimmune conditions, allergic conditions, neutrophilic dermatopathy, atopic conditions, autoinflammatory conditions, and / or T cell-mediated conditions.
[0012] For example, inflammatory skin conditions include ACD, AD, chronic spontaneous urticaria, nodular prurigo, psoriasis, psoriatic gastroenteritis, reverse psoriasis, pustular psoriasis, plaque psoriasis, psoriatic erythroderma, bacterial pustules of the folds (APF), CARD14-mediated pustular psoriasis (CAMPS), cryopyrin-associated periodic syndromes (CAPS), interleukin-1 receptor deficiency (DIRA), interleukin-36 receptor antagonist deficiency (DIRTA), hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and suppurative aseptic arthritis / necrotizing arthritis. Pyoderma / Acne Syndrome (PAPA), Pyoderma Gangrenosum (PG), Still's disease, Sweet's syndrome, Subkeratitis Pustulosis (Sneddon-Wilkinson), Acute Generalized Exanthematous Pustulosis, Infant Acne Pustulosis, Synovitis-Acne-Pustulosis-Ossification-Osteomyelitis (SAPHO) Syndrome, Intestinal Dermatitis-Arthritis Syndrome (BADAS), Neutrophilic Dermatopathy of the Dorsal Hand, Erythema Elevata Persistent, Pyodermal Pyoderma Gangrenosum, Xerosis, Dyshidrotic Eczema, Bullous Palmar Eczema, Acne Vulgaris, Contact Dermatitis, Melismia, Skin Dermatomyositis, exfoliative dermatitis, hand eczema, dyshidrotic eczema, bullous pemphigoid, pemphigus rosacea, rosacea-like dermatitis, rosacea due to sarcoidosis, rosacea due to scleroderma, rosacea due to Sweet's syndrome, rosacea due to systemic lupus erythematosus, rosacea due to urticaria, rosacea due to postherpetic dyspnea, Sweet's disease, neutrophilic hidradenitis, sterile pustules, drug eruption, urticaria, seborrheic dermatitis, pityriasis rosea, Kikuchi's disease, pruritic urticarial papules of pregnancy, Stevens-Johnson syndrome and toxic epidermal necrolysis, tattoo reaction, Wells syndrome (eosinophilic acid These include celluloid cellulitis, reactive arthritis (Reiter's syndrome), intestinal-associated dermatopathies-arthritis syndrome, rheumatoid neutrophilic dermatosis, neutrophilic eccrine hidradenitis, neutrophilic dermatopathies of the dorsal hand, plasmacytic focal balanitis, balanitis, Behçet's disease, erythema annulare centrifugally, erythema fixediformis, erythema multiforme, granuloma annulare, dermatitis of the hand, lichen styloides, lichen planus, lichen sclerosing atrophic, chronic simple lichen, lichen acanthoides, nummular eczema, sarcoidosis, subkeratotic pustulosis, urticaria, transient acantholytic dermatosis, and eczema.
[0013] In one example, an inflammatory skin condition is a form of hypersensitivity.
[0014] In some cases, the hypersensitivity is type I hypersensitivity. In some cases, type I hypersensitivity is associated with angioedema, urticaria, bee sting reactions, or latex allergy.
[0015] In some cases, the hypersensitivity is type II hypersensitivity. In some cases, type II hypersensitivity is bullous pemphigoid or pemphigus vulgaris.
[0016] In some cases, the hypersensitivity is type III hypersensitivity. In some cases, type III hypersensitivity is Henoch-Schönlein purpura, small vessel vasculitis, or systemic lupus erythematosus.
[0017] In some cases, the hypersensitivity is type IV hypersensitivity.
[0018] In some cases, type IV hypersensitivity reactions include allergic contact dermatitis, measles-like drug reactions, drug hypersensitivity syndromes (formerly known as drug reactions with drug hypersensitivity and eosinophilia [DRESS]), erythema multiforme, lichenoid drug eruption, Stevens-Johnson syndrome (SJS), or toxic epithelial necrolysis (TEN).
[0019] In some cases, the inflammatory skin condition is contact dermatitis.
[0020] In some cases, contact dermatitis is irritant contact dermatitis (ICD).
[0021] In some cases, contact dermatitis is allergic contact dermatitis (ACD). As described in the examples, the inventors found that in a mouse model of ACD, inhibition of GM-CSF and IL-5 signaling with an anti-CD131 antibody reduced the accumulation of inflammatory cells and improved the disease. Therefore, the method of this disclosure is particularly suitable for the treatment of ACD and other cell-mediated inflammatory conditions.
[0022] In some cases, inflammatory skin conditions are cell-mediated. In one case, inflammatory skin conditions are T-cell-mediated. In some cases, inflammatory skin conditions are associated with mast cell and / or neutrophil infiltration at the site of inflammation.
[0023] In some cases, the inflammatory skin condition is an antibody-mediated condition. In some cases, the inflammatory skin condition is an IgE-mediated condition and / or a condition associated with elevated serum IgE levels (e.g., atopic dermatitis). In other cases, the inflammatory skin condition is not an IgE-mediated condition and / or a condition associated with elevated serum IgE levels.
[0024] In some cases, the inflammatory skin condition is atopic dermatitis.
[0025] In some cases, the inflammatory skin condition is an autoimmune condition. In some cases, the autoimmune condition is psoriasis, systemic sclerosis, dermatomyositis, vitiligo, alopecia areata, or lichen sclerosing. In one case, the autoimmune condition is an autoimmune bullous disease. In some cases, the autoimmune bullous disease is pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, bullous pemphigus, mucosal pemphigus, bullous pemphigoid of pregnancy, herpetic dermatitis, linear IgA bullous dermatosis, acquired epidermolysis bullosa, or bullous systemic lupus erythematosus.
[0026] In some cases, inflammatory skin conditions are autoinflammatory skin diseases. In some cases, autoinflammatory skin diseases include familial Mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), hyperimmune IgD syndrome (HIDS), cryopyrin-associated periodic syndrome (CAPS), familial cold autoinflammatory syndrome (FCAS), Macklewells syndrome (MWS), neonatal-onset multi-system inflammatory disease / chronic infantile neurogenic cutaneous arthritis syndrome (NOMID / CINCA), and suppurative aseptic arthritis / necrotizing arthritis. These include pyoderma angina / acne syndrome (PAPA syndrome, PAPAS, PAPGA syndrome), juvenile generalized granulomatosis (Blau syndrome, juvenile-onset sarcoidosis), interleukin-1 receptor deficiency (DIRA), mevalonaciduria, Majid syndrome, Schnitzler syndrome, Behçet's disease, hidradenitis suppurativa, or periodic fever syndromes, aphthous stomatitis, pharyngitis, and adenitis (PAPAS, PFAPA syndrome).
[0027] In some cases, the inflammatory skin condition is neutrophilic dermatosis. In one case, neutrophilic dermatosis is a bacterial pustule of the folds (APF), plaque psoriasis, CARD14-mediated pustular psoriasis (CAMPS), cryopyrin-associated periodic syndromes (CAPS), interleukin-1 receptor deficiency (DIRA), interleukin-36 receptor antagonist deficiency (DIRTA), hidradenitis suppurativa (HS), palmoplantar pustulosis, septic arthritis, pyoderma gangrenosum, acne syndrome (PAPA), pyoderma gangrenosum, acne, hidradenitis suppurativa (PASH). These include pyoderma gangrenosum (PG), skin lesions of Behçet's disease, Still's disease, Sweet's syndrome, subkeratotic pustulosis (Sneddon-Wilkinson), pustular psoriasis, palmoplantar pustulosis, acute generalized exanthematous pustulosis, pustulosis of the extremities of infants, synovitis-acne-pustulosis-hyperossification-osteomyelitis (SAPHO) syndrome, gut-associated dermatosis-arthritis syndrome (BADAS), neutrophilic dermatosis of the dorsal hand, neutrophilic eccrine hidradenitis, persistent erythema elevateds, or pyoderma gangrenosum. In one example, neutrophilic dermatosis may be hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP).
[0028] The inventors found that in a mouse model of ACD, administration of an antibody that binds to CD131 and neutralizes signaling by GM-CSF and IL-5 reduced swelling, mast cell infiltration, eosinophil infiltration, CD8+ T cell infiltration, and neutrophil infiltration compared to mice administered with an isotype control antibody. Therefore, in some cases, administration of a compound that binds to CD131 and neutralizes signaling by GM-CSF and IL-5: a) Reduce swelling at the site of inflammation, and / or b) Reduce mast cell infiltration at the site of inflammation, and / or c) Reduce neutrophil infiltration at the site of inflammation.
[0029] In some cases, administration of compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling: a) Reduce swelling at the site of inflammation, and / or b) Reduce mast cell infiltration at the site of inflammation, and / or c) Reduce neutrophil infiltration at the site of inflammation, and / or d) Reduce CD8+ T cell infiltration at the site of inflammation, and / or e) Reduce neutrophil infiltration at the site of inflammation.
[0030] In some cases, administration of compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling: a) Reduce CD8+ T cell infiltration at the site of inflammation, and / or b) Reduce neutrophil infiltration at the site of inflammation.
[0031] A preferred method for evaluating the above is described herein and will be known to those skilled in the art.
[0032] In some cases, compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling also neutralize IL-3 signaling.
[0033] In one example, a compound that binds to CD131 and neutralizes signal transduction by GM-CSF and IL-5 inhibits GM-CSF-induced proliferation of TF-1 cells at an IC 50 of at least 600 nM or 500 nM. For example, the IC 50 is at least about 400 nM. For example, the IC 50 is at least about 300 nM or 200 nM or 100 nM. For example, the IC 50 is at least about 50 nM. For example, the IC 50 is at least about 10 nM or 5 nM or 1 nM. In one example, the IC 50 is at least about 1 nM. For example, the IC 50 is at least about 0.9 nM or 0.8 nM or 0.6 nM. In one example, the IC 50 is at least about 0.5 nM. In one example, the IC 50 is at least about 0.4 nM. In one example, the IC 50 is at least about 0.3 nM.
[0034] In one example, a compound that binds to CD131 and neutralizes signal transduction by GM-CSF and IL-5 inhibits IL-5-induced proliferation of TF-1 cells at an IC 50 of at least 600 nM or 500 nM. For example, the IC 50 is at least about 400 nM. For example, the IC 50 is at least about 300 nM or 200 nM or 100 nM. For example, the IC 50 is at least about 50 nM. For example, the IC 50 is at least about 10 nM or 5 nM or 1 nM. In one example, the IC 50 is at least about 5 nM. For example, the IC 50 is at least about 4 nM. In one example, the IC 50 is at least about 4.5 nM or at least about 4.6 nM or at least about 4.7 nM. In one example, the IC 50 is at least about 4.6 nM.
[0035] For example, a compound that binds to CD131 and neutralizes signaling by GM-CSF and IL-5 contains at least 600 nM or 500 nM IC50. 50 This inhibits IL-3-induced proliferation of TF-1 cells. For example, IC 50 It is at least about 400 nM. For example, IC 50 It is at least about 300 nM, 200 nM, or 100 nM. For example, IC 50 It is at least about 50 nM. For example, IC 50 It is at least about 10 nM, 5 nM, or 1 nM. For example, IC 50 It is at least about 1 nM. For example, IC 50 This is at least about 0.9 nM, 0.8 nM, or 0.6 nM. For example, IC 50 It is at least about 0.5 nM. For example, IC 50 This is at least about 0.2 nM or at least about 0.1 nM. For example, IC 50 It is at least about 0.15 nM.
[0036] I C 50 A method for determining this is described herein, and before adding the relevant growth factors (GM-CSF, IL-3 and / or IL-5), TF-1 cells (e.g., about 1 × 10⁶) are subjected to the presence of a compound that binds to CD131 (e.g., for at least about 3 minutes or 1 hour, e.g., about 30 minutes). 4 The process involves culturing individual TF-1 cells, further culturing the cells (for example, for at least about 48 hours, or at least about 72 hours, or at least about 96 hours, for example, about 72 hours), and then determining cell proliferation. Cell proliferation is 3 The cells were grown for approximately 6 hours in the presence of [H]-thymidine. 3 By determining the incorporation of [H]-thymidine, for example, by liquid scintillation counting, IC can be determined. 50 It is possible to make a decision.
[0037] In some cases, compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling are a) GM-CSF-induced proliferation of TF-1 cells with an IC50 of at least 100 nM, and / or b) IL-5-induced proliferation of TF-1 cells with an IC50 of at least 100 nM, and / or c) Inhibit IL-3-induced proliferation of TF-1 cells with an IC50 of at least 100 nM.
[0038] In some cases, compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling are a) GM-CSF-induced proliferation of TF-1 cells with an IC50 of at least 50 nM, and / or b) IL-5 induced proliferation of TF-1 cells with an IC50 of at least 50 nM, and / or c) Inhibit IL-3-induced proliferation of TF-1 cells with an IC50 of at least 50 nM.
[0039] In some cases, compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling are a) GM-CSF-induced proliferation of TF-1 cells with an IC50 of at least 10 nM, and / or b) IL-5 induced proliferation of TF-1 cells with an IC50 of at least 10 nM, and / or c) Inhibit IL-3-induced proliferation of TF-1 cells with an IC50 of at least 10 nM.
[0040] In one example, compounds that bind to CD131 reduce or prevent IL-3 and / or GM-CSF-induced STAT-5 signaling.
[0041] For example, a compound that binds to CD131 has an IC of approximately 20 nM or less. 50 This reduces or prevents IL-3-induced STAT-5 signaling. For example, pStat-5 IC 50 IL-3 is approximately 10 nM or less, or approximately 9 nM or less, or approximately 8 nM or less. One example is pStat-5 IC.50 IL-3 is approximately 7.5 nM or less, for example, 7.3 nM.
[0042] For example, a compound that binds to CD131 has an IC of approximately 60 nM or less. 50 This reduces or prevents GM-CSF-induced STAT-5 signaling. For example, pStat-5 IC 50 GM-CSF is approximately 50 nM or less, or approximately 45 nM or less, or approximately 40 nM or less. For example, the compound that binds to CD131 is IC20 or less. 50 This reduces or prevents GM-CSF-induced STAT-5 signaling.
[0043] For example, the compound can be brought into contact with cells containing a β-lactamase reporter gene (e.g., TF-1 cells) in the presence of IL-3 and / or GM-CSF, under the control of the interferon regulator 1 (irf1) response element. The cells can also be brought into contact with a suitable substrate (e.g., a negatively charged fluorescent β-lactamase substrate such as CCF2 or CCF4) to determine the change in the signal (e.g., fluorescence). A reduction in the change in the signal in a positive control (i.e., cells brought into contact with IL-3 and / or GM-CSF in the absence of the protein or antibody) indicates that the compound reduces or prevents IL-3 and / or GM-CSF-induced STAT-5 signaling.
[0044] For example, a compound that binds to CD131 has one or more of the following activities: (i) Reducing or inhibiting the activation of isolated human neutrophils by GM-CSF, as determined by reducing or inhibiting the GM-CSF-induced increase in neutrophil cell size. (ii) Reduce or inhibit IL-3-induced IL-8 secretion by human basophils, (iii) To reduce or prevent IL-3-mediated survival or plasmacytoid dendritic cells (pDCs), (iv) Reduce or prevent IL-5-mediated activation of human peripheral blood eosinophils, as determined by evaluating changes in forward scattering as assessed by flow cytometry. (v) To reduce or prevent the survival of human peripheral blood eosinophils in the presence of IL-5 and / or GM-CSF and / or IL-3, (vi) Reduce or prevent the release of IL-3-induced tumor necrosis factor (TNF)α from human mast cells. (vii) Reduce or prevent IL-3-induced IL-13 release from human mast cells, (viii) Reduce or prevent the enhancement of IgE-mediated IL-8 release from human mast cells by IL-3 and / or IL-5 and / or GM-CSF. (ix) To reduce or prevent the formation of colony-forming unit-granulocyte-macrophage (CFU-GM) by CD34+ human bone marrow cells cultured in the presence of stem cell factor (SCF), GM-CSF, IL-3, and IL-5. (x) To reduce the size or weight of polyps in a mouse xenograft model of human nasal polypitis, and / or (xi) To reduce the number of B cells in polyps in a mouse xenograft model of human nasal polypopathy.
[0045] In one example, compounds that bind to CD131 do not substantially or significantly inhibit the proliferation of TF-1 cells in response to one or more of erythropoietin, IL-6, IL-4, or stem cell factors. Methods for determining the ability of compounds to bind to CD131 and inhibit the proliferation of TF-1 cells in relation to cytokines or growth factors are described herein and are readily applicable to the embodiments of this disclosure.
[0046] In some cases, the compounds that bind to CD131 and neutralize GM-CSF and IL-5 signaling are proteins containing an antigen-binding site that binds to CD131. In some cases, the antigen-binding site is the antigen-binding site of an antibody or a single-domain antibody. In some cases, the antigen-binding site contains one or more CDRs.
[0047] In this specification, references to compounds, proteins, or antibodies that "bind" to CD131 provide literal supports for compounds, proteins, or antibodies that "bind specifically" or "specifically bind to" CD131.
[0048] For example, the K protein for polypeptides containing the sequence described in Sequence ID No. 5 D In this case, the polypeptide is immobilized on a solid surface, K D If it is determined by surface plasmon resonance, it is approximately 10 nM or less.
[0049] For example, K D This is 10 nM or less, for example, 5 nM or less, 4 nM or less, or 3 nM or less, or 2 nM or less. For example, K D It is less than 1 nM. For example, K D This is 0.9 nM or less, or 0.7 nM or less, or 0.8 nM or less, or 0.7 nM or less, or 0.6 nM or less. For example, K D It is less than 0.5 nM. For example, K D It is less than 0.4 nM. For example, K D It is less than 0.3 nM. For example, K D It is less than 0.2 nM.
[0050] For example, proteins containing antigen-binding sites are evaluated using a competitive assay with labeled and unlabeled proteins or antibodies, for instance, to determine a K content of approximately 10 nM or less. D It binds to cells that express CD131 (e.g., neutrophils, eosinophils, or TF-1 cells). In one example, K DThis is 5nM or less, or 4nM or less, or 3nM or less, or 2nM or less. For example, K D It is less than 1 nM. For example, K D The concentration is 0.9 nM or less, or 0.7 nM or less, or 0.8 nM or less, or 0.7 nM or less, or 0.6 nM or less.
[0051] For example, K D For neutrophils, the value is approximately 300 nM or less.
[0052] For example, K D The value for eosinophils is approximately 700 nM or less.
[0053] For example, K D This is approximately 400 nM or less for TF-1 cells.
[0054] For example, a protein containing an antigen-binding site is a protein containing one or more antibody-variable regions. For example, a protein contains a heavy chain variable region (V H ) includes. For example, a protein has a light chain variable region (V L ) contains. For example, the protein is V H and V L Includes. In some examples, V H and V L In other examples, V H and V L These are located within separate polypeptide chains.
[0055] In some cases, the protein is a single-domain antibody (sdAb).
[0056] In some examples, the protein contains Fv.
[0057] In some examples, Root is (i) single chain Fv fragment (scFv), (ii) Dimer scFv (di-scFv), or (iii) Diabody, (iv) Triabody, (v) Tetrabody, (vi)Fab, (vii)F(ab')2, (viii)Fv, (ix) Antibody, Fc, or heavy chain constant domain (C H )2 and / or C H One of (i) to (viii) connected to the steady region of 3, (x) albumin or a functional fragment or variant thereof, or one of (i) to (viii) linked to a protein that binds to albumin, (xi) Selected from the group consisting of antibodies.
[0058] In some examples, Root is (i) single chain Fv fragment (scFv), (ii) Dimer scFv (di-scFv), or (iii) Diabody, (iv) Triabody, (v) Tetrabody, (vi)Fab, (vii)F(ab')2, (viii)Fv, (ix) Antibody, Fc, or heavy chain constant domain (C H )2 and / or C H One of (i) to (viii) connected to the steady region of 3, (x) albumin, its functional fragment or variant, or one of (i) to (viii) linked to an albumin-binding protein (e.g., an antibody or its antigen-binding fragment), (xi) Selected from the group consisting of antibodies.
[0059] For example, a protein contains an Fc region.
[0060] For example, a protein contains one or more amino acid substitutions that increase the protein's half-life. For example, an antibody contains an Fc region that includes one or more amino acid substitutions that increase the affinity of the Fc region to the embryonic Fc receptor (FcRn).
[0061] In one example, the protein is an antibody, such as a monoclonal antibody. In another example, the antibody is a naked antibody.
[0062] For example, a protein (or antibody) may be chimeric, non-immunized, humanized, humanized, or primate-like.
[0063] In one example, the protein or antibody is human. Examples of antibodies include 9A2-VR24.29 (also known as "CSL311") described in WO2017 / 088028, and BION-1 described in Sun et al. (1999) Blood 94:1943-1951.
[0064] For example, a protein may contain IgG constant regions, such as human constant regions, e.g., IgG1, IgG2, IgG3, or IgG4 constant regions, or mixtures thereof. H and V L For proteins containing V H It can be linked to the heavy chain steady region, V L This can be linked to the light chain constant region.
[0065] The heavy chain constant region of all antibodies (or constant region or C) H The C-terminal lysine of proteins (including 3) can be removed, for example, during the production or purification of the protein or antibody, or by recombining and manipulating the nucleic acid encoding the heavy chain. Therefore, a total antibody (or CD131-conjugated compound) may include a population from which all C-terminal lysine residues have been removed, a population from which C-terminal lysine residues have not been removed, and / or a population having a mixture of proteins that contain or do not contain C-terminal lysine residues. In some examples, the population may further include proteins from which a C-terminal lysine residue has been removed in one of the heavy chain constant regions. Similarly, a total antibody composition may include the same or similar mixtures of antibody populations that contain or do not contain C-terminal lysine residues.
[0066] In one example, the protein is present in the composition. For example, the composition comprises a protein containing an antigen-binding site or antibody as described herein. In one example, the composition further comprises one or more variants of the protein or antibody. For example, variants lacking an encoded C-terminal lysine residue, deamide variants and / or glycosylated variants and / or variants containing pyroglutamate, for example, variants at the N-terminus of a protein and / or variants lacking an N-terminal residue, for example, variants containing all or part of the N-terminal glutamine and / or secretory signal in an antibody or V-region. A deamide variant of an encoded asparagine residue may produce isoaspartic acid and aspartic acid isoforms, or succinamide with adjacent amino acid residues. A deamide variant of an encoded glutamine residue may result in glutamic acid. Compositions comprising heterogeneous mixtures of such sequences and variants are intended to be included when a particular amino acid sequence is referenced.
[0067] For example, the protein or antibody described herein includes a constant region of an IgG4 antibody or a stabilized constant region of an IgG4 antibody. For example, the protein or antibody includes an IgG4 constant region having proline at position 241 (according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, Washington DC, United States Department of Health and Human Services, 1987 and / or 1991)).
[0068] In one example, the heavy chain constant region includes the sequence described in Sequence ID No. 16. In another example, the protein, or a composition containing a protein, includes a heavy chain constant region which includes a stabilized heavy chain constant region, comprising a mixture of sequences that may or may not include a C-terminal lysine residue, either entirely or partially.
[0069] In some cases, the protein binds to CD131 and contains the sequence described in SEQ ID NO: 6. H and V containing the sequence described in Sequence ID 7L It contains an antibody variable region that competitively inhibits the binding of antibody 9A2-VR24.29 to CD131.
[0070] In some cases, the protein binds to CD131 and contains the sequence described in SEQ ID NO: 6. H It includes a light chain containing the sequence described in Sequence ID No. 7, and an antibody variable region that competitively inhibits the binding of antibody 9A2-VR24.29 to CD131.
[0071] In some cases, the protein binds to CD131 and contains the sequence described in SEQ ID NO: 6. H V containing the sequence described in Sequence ID No. 18 L It contains an antibody variable region that competitively inhibits the binding of antibody 9A2-VR24.29 to CD131.
[0072] In some cases, the protein contains the sequence described in SEQ ID NO: 6. H and V containing the sequence described in Sequence ID 7 L The antibody 9A2-VR24.29 against CD131, which includes [specific components], binds to the same or overlapping epitopes within CD131.
[0073] In some cases, the protein contains the sequence described in SEQ ID NO: 6. H The light chain containing the sequence described in Sequence ID No. 7, and the antibody 9A2-VR24.29 against CD131, which binds to the same or overlapping epitopes within CD131.
[0074] In some cases, the protein contains the sequence described in SEQ ID NO: 6. H V containing the sequence described in Sequence ID No. 18 L The antibody 9A2-VR24.29 against CD131, which includes [specific components], binds to the same or overlapping epitopes within CD131.
[0075] In some cases, the antigen-binding site binds to an epitope within site 2 of CD131. In this regard, those skilled in the art will recognize that site 2 of CD131 is composed of residues from two CD131 polypeptides that form a dimer, for example, site 2 includes residues in loops AB and EF of domain 1 of one CD131 polypeptide, and residues in loops BC and FG of the other CD131 polypeptide.
[0076] In some cases, the antigen-binding site binds to an epitope formed during the dimerization of two CD131 polypeptides.
[0077] In some cases, the antigen-binding site binds to residues in domain 1 of one CD131 polypeptide and residues in domain 4 of another CD131 polypeptide. In one example, the residues in domain 1 of CD131 include residues in the region 101-107 of SEQ ID NO: 1, and / or the residues in domain 4 of CD131 include residues in the region 364-367 of SEQ ID NO: 1.
[0078] In some examples, Root is a) One or more amino acids in a CD131 polypeptide chain corresponding to positions 39, 101, 102, 104, 105, 106, and 107 of SEQ ID NO: 1, b) Binds to an epitope containing amino acids in another CD131 polypeptide chain corresponding to one or more of the amino acids at positions 364, 365, 366, 367, 420, and 421 of SEQ ID NO: 1.
[0079] In some cases, the protein contains the amino acid sequence described in SEQ ID NO: 6. H Includes 3 CD-Rs H V containing the amino acid sequence described in Sequence ID No. 7 L Includes 3 CD-Rs L It includes an antibody variable region.
[0080] In some cases, the protein contains the amino acid sequence described in SEQ ID NO: 6. HV comprising three CDRs H and V comprising three CDRs of a light chain comprising the amino acid sequence set forth in SEQ ID NO: 7 L comprising an antibody variable region.
[0081] In some examples, the protein is V comprising three CDRs of V H comprising the amino acid sequence set forth in SEQ ID NO: 6 H and V comprising three CDRs of V comprising the amino acid sequence set forth in SEQ ID NO: 18 L comprising an antibody variable region. L comprising an antibody variable region.
[0082] In some examples, the protein is a) HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 8 or a sequence having 1, 2, or 3 or fewer amino acid substitutions relative to SEQ ID NO: 8, HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 9 or a sequence having 1, 2, or 3 or fewer amino acid substitutions relative to SEQ ID NO: 9, and HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10 or a sequence having 1, 2, or 3 or fewer amino acid substitutions relative to SEQ ID NO: 10, and V H and b) LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11 or a sequence having 1, 2, or 3 or fewer amino acid substitutions relative to SEQ ID NO: 11, LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12 or a sequence having 1, 2, or 3 or fewer amino acid substitutions relative to SEQ ID NO: 12, and LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13 or a sequence having 1, 2, or 3 or fewer amino acid substitutions relative to SEQ ID NO: 13, and V L comprising.
[0083] In some examples, the protein is a) HCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 8, HCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 9, and HCDR3 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 10, and VH and b) a V comprising an LCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 11, an LCDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 12, and an LCDR3 comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 13 L comprising the same
[0084] In some examples, the protein comprises a V comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 6 H and a V comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 7 L comprising the same
[0085] In some examples, the protein comprises a V comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 6 H and a light chain comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 7
[0086] In some examples, the protein comprises a V comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 6 H and a V comprising an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 18 L comprising the same
[0087] In some examples, the protein comprises a V comprising the amino acid sequence set forth in SEQ ID NO: 6 H and a V comprising the amino acid sequence set forth in SEQ ID NO: 7 L comprising the same
[0088] In some cases, the protein contains the amino acid sequence described in SEQ ID NO: 6. H It includes a light chain V region containing the amino acid sequence described in Sequence ID No. 7.
[0089] In some cases, the protein contains the amino acid sequence described in SEQ ID NO: 6. H V containing the amino acid sequence described in Sequence ID No. 18 L This includes.
[0090] In some examples, the protein comprises a heavy chain containing an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 14, and a light chain containing an amino acid sequence having at least 70%, at least 80%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 15.
[0091] In some examples, the protein comprises a heavy chain containing the amino acid sequence described in SEQ ID NO: 14 and a light chain containing the amino acid sequence described in SEQ ID NO: 15.
[0092] Sequence list key Sequence ID 1: Amino acid sequence of Homo sapiens CD131 Sequence ID 2: Amino acid sequence of the Homo sapiens IL-3 receptor α Sequence ID 3: Amino acid sequence of the Homo sapiens GM-CSF receptor Sequence ID 4: Amino acid sequence of the Homo sapiens IL-5 receptor Sequence ID 5: Amino acid sequence of soluble Homo sapiens CD131 containing a C-terminal 6×His tag. Sequence ID 6: 9A2-VR24.29 V H amino acid sequence Sequence ID 7: 9A2-VR24.29 V L amino acid sequence Amino acid sequence of HCDR1 at SEQ ID NO: 8:9A2-VR24.29 Amino acid sequence of HCDR2 at SEQ ID NO: 9A2-VR24.29 Amino acid sequence of HCDR3 at SEQ ID NO: 10:9A2-VR24.29 Amino acid sequence of LCDR1 of SEQ ID NO: 11:9A2-VR24.29 Amino acid sequence of LCDR2 of SEQ ID NO: 12:9A2-VR24.29 Amino acid sequence of LCDR3 of SEQ ID NO: 13:9A2-VR24.29 Amino acid sequence of the heavy chain of SEQ ID NO: 14:9A2-VR24.29 Amino acid sequence of the light chain of sequence number 15:9A2-VR24.29 Sequence ID 16: Amino acid sequence of the constant region of the stabilized IgG quadrichain Sequence ID 17: Amino acid sequence of the constant region of the kappa light chain Sequence ID 18: 9A2-VR24.29 V L amino acid sequence [Brief explanation of the drawing]
[0093] [Figure 1] This graph shows the change in ear thickness in the ACD mouse model described in Example 2. Ear thickness treated with vehicle and DNFB was measured daily for 12 days after DNFB rechallenge. Ear swelling was determined as the difference in ear thickness before and after each induction. Data: Mean + SEM; n=5-11 mice, results from three independent experiments combined **p<0.01, two-way ANOVA with Bonferroni post-hoc test for shown comparisons. [Figure 2] This graph shows the change in epidermal thickness in the ACD mouse model described in Example 2. Left panel: Measurement of ear epidermal thickness. Right panel: Difference in epidermal thickness between DNFB-treated ear and vehicle-treated ear. Data: Mean values; n=5-11 mice, combined results from three independent experiments ***p<0.001, two-way ANOVA with Bonferroni post-hoc test for shown comparisons. ##p<0.01, unpaired t-test. [Figure 3]This graph shows the change in mast cell count on day 12 in the ACD mouse model described in Example 2. Left panel: Number of cutaneous mast cells in ear tissue at the completion of the ACD experiment, detected by toluidine blue staining. Right panel: Increase ratio of mast cell count in DNFB-treated ear / vehicle-treated ear in individual mice. Data: Mean + SEM; n=5-11 mice, combining results from three independent experiments ***p<0.001, two-way ANOVA with Bonferroni post-hoc test for shown comparisons. ##p<0.01, unpaired t-test. [Figure 4] This graph shows the change in neutrophil cell count on day 12 in the ACD mouse model described in Example 2. Left panel: At the completion of the ACD experiment, the ratio of neutrophils in the vehicle and DNFB-treated ears of different treatment groups was evaluated by flow cytometry. Right panel: The ratio of increase in the neutrophil ratio between the DNFB-treated ear and the vehicle-treated ear in individual mice. [Figure 5] This graph shows the change in eosinophil cell count on day 12 in the ACD mouse model described in Example 2. Left panel: At the completion of the ACD experiment, the ratio of eosinophils in the vehicle and DNFB-treated ears of different treatment groups was evaluated by flow cytometry. Right panel: The ratio of increase in the eosinophil ratio in the DNFB-treated ear / vehicle-treated ear in individual mice. [Figure 6] This graph shows the change in CD8+ T cell count on day 6 in the ACD mouse model described in Example 2. Left panel: Flow cytometry was used to evaluate the ratio of CD8+ T cells in the vehicle-treated and DNFB-treated ears of different treatment groups on day 6 of the ACD experiment. Right panel: The multiplier of increase in the ratio of CD8+ T cells in the DNFB-treated ear / vehicle-treated ear in individual mice. [Figure 7]This graph shows the change in neutrophil cell count on day 6 in the ACD mouse model described in Example 2. Left panel: Flow cytometry was used to evaluate the ratio of neutrophils in the vehicle-treated and DNFB-treated ears of different treatment groups on day 6 of the ACD experiment. Right panel: The multiplier of increase in the ratio of neutrophils in the DNFB-treated ear / vehicle-treated ear in individual mice. [Figure 8] This graph shows the change in eosinophil cell count on day 6 in the ACD mouse model described in Example 2. Left panel: Flow cytometry was used to evaluate the ratio of eosinophils in the vehicle-treated and DNFB-treated ears of different treatment groups on day 6 of the ACD experiment. Right panel: The ratio of increase in the eosinophil ratio between the DNFB-treated ear and the vehicle-treated ear in individual mice. [Figure 9] This graph shows the change in mast cell count on day 6 in the ACD mouse model described in Example 2. Left panel: Flow cytometry was used to evaluate the ratio of mast cells in the vehicle-treated and DNFB-treated ears of different treatment groups on day 6 of the ACD experiment. Right panel: The multiplier of increase in the ratio of mast cells in the DNFB-treated ear / vehicle-treated ear in individual mice. [Figure 10] This graph shows the change in ear thickness in an AD mouse model, as described in Example 3. The thickness of the ear pinner was measured at 24-hour intervals for 10 days. CSL311 or isotype mAb (10 mg / kg) was intravenously injected into the tail vein of hβcTg mice on days 1, 3, and 5, as indicated by the arrows. [Modes for carrying out the invention]
[0094] General Throughout this specification, unless otherwise specified or the context indicates, references to a single step, composition of a substance, group of steps, or group of compositions of a substance should be taken to encompass one or more (i.e., one or more) of those steps, compositions of a substance, group of steps, or group of compositions of a substance.
[0095] Those skilled in the art will understand that this disclosure is susceptible to variations and modifications other than those specifically described. It should be understood that this disclosure includes all such variations and modifications. This disclosure also includes all steps, features, compositions and compounds that are individually or collectively referred to or shown herein, as well as any combination of any or all of such steps or features, or any two or more of them.
[0096] This disclosure should not be limited in scope by the specific examples described herein, which are for illustrative purposes only. Functionally equivalent products, compositions, and methods are clearly within the scope of this disclosure.
[0097] Any example in this disclosure shall apply mutatis mutandis to any other example in this disclosure unless otherwise specified.
[0098] Unless otherwise specifically defined, all technical and scientific terms used herein shall be construed to have the same meaning as that generally understood by those skilled in the art (e.g., immunology, immunohistochemistry, protein chemistry, and biochemistry).
[0099] Unless otherwise indicated, the recombinant proteins, cell cultures, and immunological techniques used in this disclosure are standard procedures well known to those skilled in the art. Such techniques are described in J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989), TA Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), DMGlover and BDHames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and FMAusubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates to date), Ed Harlow and David Lane (editors), Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and JEColigan et al. This is described and explained throughout the literature in sources such as al. (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates to date).
[0100] The descriptions and definitions of variable regions and parts thereof, immunoglobulins, antibodies, and their fragments in this specification can be further clarified by the discussions in Kabat Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., 1987 and 1991; Bork et al., J Mol. Biol. 242, 309-320, 1994; Chothia and Lesk J. Mol Biol. 196:901-917, 1987; Chothia et al. Nature 342, 877-883, 1989; and / or Al-Lazikani et al., J Mol Biol 273, 927-948, 1997.
[0101] The term "and / or," for example, "X and / or Y," must be understood to mean either "X and Y" or "X or Y," and should be interpreted as explicitly supporting both meanings or either one of them.
[0102] Throughout this specification, it will be understood that the words “comprise,” or variations such as “comprises,” or “comprising,” mean the inclusion of a specified element, integer, or step, or a group of elements, integers, or steps, but not the exclusion of any other element, integer, or step, or a group of elements, integers, or steps.
[0103] Selected definition For nominal purposes only and not for limitation, exemplary sequences of human CD131 (pre-CD131) are described in NCBI reference sequence: NP_000386.1 and NCBI Genbank registration number P32927 (also described in Sequence ID No. 1). The sequence of mature human CD131 lacks amino acids 1-16 of Sequence ID No. 1. The amino acid positions are often referred to herein with reference to pre-CD131. The positions in mature CD131 are readily determined by considering the signal sequence (amino acids 1-16 in the case of Sequence ID No. 1). The sequences of CD131 from other species can be determined using sequences provided herein and / or in publicly available databases, and / or using standard techniques (e.g., as described in Ausubel et al., (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates to date) or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)). References to human CD131 may be abbreviated as hCD131. References to soluble CD131 refer to the extracellular region of CD131, e.g., the polypeptide containing amino acids 17-438 of SEQ ID NO: 1.
[0104] References to CD131 in this specification include the native forms and mutants of CD131 that retain the ability to bind to CD131 (e.g., hCD131) and induce signal transduction. CD131 is also known as "CSF2RB," "cytokine receptor common subunit β," and "β (beta) common receptor" (abbreviated as "βCR" or "βc").
[0105] The “compounds” contemplated in this disclosure may take any of the various forms, including natural compounds, chemical small molecule compounds, or biocompounds or macromolecules. Exemplary compounds include antibodies or antigen-binding fragments of antibodies, nucleic acids, polypeptides, peptides, and proteins, including small molecules.
[0106] As used herein, the terms “disease” or “condition” refer to the disruption or interference of normal function, and are not limited to any specific condition, disease, or disorder.
[0107] As used herein, the terms “to treat,” “to cure,” or “to treat” include administering any of the compounds described herein to alleviate, prevent, or eliminate at least one symptom of a specified disease or condition.
[0108] As used herein, the terms “preventing,” “prevent,” or “prevention” include administering any of the compounds described herein to thereby halt or inhibit the development of at least one symptom of a condition, for example, before the symptoms fully develop in a subject.
[0109] As used herein, the term “subject” is interpreted to mean any animal, including humans and, for example, mammals. Examples of subjects include, but are not limited to, humans and non-human primates. In one example, the subject is a human.
[0110] The term “protein” should be interpreted to include a single polypeptide chain, i.e., a series of consecutive amino acids linked by peptide bonds, or a series of polypeptide chains linked to one another by covalent or non-covalent bonds (i.e., a polypeptide complex). For example, a series of polypeptide chains may be covalently linked using preferred chemical bonds or disulfide bonds. Examples of non-covalent bonds include hydrogen bonds, ionic bonds, van der Waals forces, and hydrophobic interactions. In some examples, a protein is a fusion protein. As used herein, a “fusion protein” is a protein that contains at least two domains linked together so that they are translated as a single unit that produces a single protein.
[0111] The terms "polypeptide" or "polypeptide chain" are understood, from the preceding paragraph, to mean a series of amino acids linked by peptide bonds.
[0112] The terms “isolated protein” or “isolated polypeptide” refer to a protein or polypeptide that, based on its origin or source of derivative, is not associated with any naturally associated components in its natural state and substantially contains no other proteins from the same source. A protein can be substantially free of naturally associated components or substantially purified by isolation using protein purification techniques known in the art. “Substantially purified” means that the protein is substantially free of contaminants, for example, free of contaminants in a percentage of at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.
[0113] The term "recombinant" must be understood to mean the product of artificial genetic modification. Therefore, in relation to recombinant proteins containing antibody-antigen-binding domains, this term does not encompass naturally occurring antibodies within the subject's body, which are naturally occurring recombinant products that arise during B-cell maturation. However, if such antibodies are isolated, they should be considered isolated proteins containing antibody-antigen-binding domains. Similarly, when a nucleic acid encoding a protein is isolated and expressed using recombinant means, the resulting protein is a recombinant protein containing an antibody-antigen-binding domain. Recombinant proteins also encompass proteins expressed by artificial recombinant means, for example, when they are present in the cells, tissues, or subjects in which they express.
[0114] As used herein, the term “antigen-binding site” is interpreted to mean a structure formed by a protein that can bind to or specifically bind to an antigen. The antigen-binding site does not have to be a series of consecutive amino acids or amino acids within a single polypeptide chain. For example, in Fv produced from two different polypeptide chains, the antigen-binding site is the V that interacts with the antigen. L and V H It is composed of a series of amino acids, which are generally present but not necessarily in one or more CDRs in each variable region. In some cases, the antigen-binding site is V H Or V L Or Fv, or V H Or V L Or it includes Fv. In some examples, the antigen-binding site includes one or more CDRs of the antibody.
[0115] Those skilled in the art will know that an "antibody" is a variable region consisting of multiple polypeptide chains, for example, V L polypeptides and V H It will be recognized that antibodies are generally considered to be proteins containing polypeptides. Antibodies also generally contain constant domains, some of which, in the case of heavy chains, can be located in constant regions containing constant fragments or fragment crystals (Fc). H and VL These interact to form an Fv containing an antigen-binding region that can specifically bind to one or more closely related antigens. Generally, mammalian light chains are either κ or λ light chains, and mammalian heavy chains are α, δ, ε, γ, or μ. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. The term “antibody” also encompasses humanized antibodies, primate-derived antibodies, human antibodies, and chimeric antibodies.
[0116] The terms "full-length antibody," "intact antibody," or "whole antibody" are used interchangeably to refer to an antibody in a substantially intact form, as opposed to an antigen-binding fragment of an antibody. Specifically, whole antibodies include those with heavy and light chains containing the Fc region. The constant domain may be the wild-type sequence constant domain (e.g., the human wild-type sequence constant domain) or an amino acid sequence variant thereof.
[0117] As used herein, “variable region” refers to a portion of the light and / or heavy chain of an antibody as defined herein, which is capable of specifically binding to an antigen and includes the amino acid sequences of complementarity-determining regions (CDRs), i.e., CDR1, CDR2, and CDR3, as well as a framework region (FR). An exemplary variable region includes three or four FRs (e.g., FR1, FR2, FR3, and optionally FR4) along with three CDRs. In the case of proteins derived from IgNARs, the protein may lack CDR2. H This refers to the variable region of the heavy chain. L This refers to the variable region of the light chain.
[0118] As used herein, the term “complementarity-determining region” (synonym CDR; i.e., CDR1, CDR2, and CDR3) refers to amino acid residues in the antibody variable region necessary for antigen binding. Each variable region typically has three CDR regions, identified as CDR1, CDR2, and CDR3. The amino acid positions assigned to CDR and FR may be defined according to Kabat's Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., 1987 and 1991 or other numbering systems in practice of this disclosure, e.g., the classical numbering system of Chothia and Lesk J. Mol Biol. 196:901-917, 1987, the IMGT numbering system of Chothia et al. Nature 342, 877-883, 1989, and / or Al-Lazikani et al., J Mol Biol 273:927-948, 1997, Lefranc et al., Devel. And Compar. Immunol., 27:55-77, 2003; or the AHO numbering system of Honnegher and Plukthun J. Mol. Biol., 309:657-670, 2001. For example, according to Kabat's numbering system, V H The framework regions (FR) and CDRs are arranged as follows: residues 1-30 (FR1), 31-35 (CDR1), 36-49 (FR2), 50-65 (CDR2), 66-94 (FR3), 95-102 (CDR3), and 103-113 (FR4). According to Kabat's numbering system, V L FR and CDR are located as follows: residues 1-23 (FR1), 24-34 (CDR1), 35-49 (FR2), 50-56 (CDR2), 57-88 (FR3), 89-97 (CDR3), and 98-107 (FR4). This disclosure is not limited to, but includes, all numbering systems, including those discussed above, as defined by the Kabat numbering system. For example, references to CDR (or FR) in this specification refer to these regions by the Kabat numbering system.
[0119] The "framework region" (FR) consists of variable region residues other than CDR residues.
[0120] As used herein, the term "Fv" means V, whether consisting of multiple polypeptides or a single polypeptide. L and V H It is interpreted that these associate to form a complex having an antigen-binding site, that is, any protein that can specifically bind to an antigen. H and V L These may be within a single polypeptide chain or within different polypeptide chains. Furthermore, Fv (and any protein in this disclosure) may have multiple antigen-binding sites that may or may not bind to the same antigen. This term should be understood to encompass fragments directly derived from antibodies, as well as proteins corresponding to such fragments produced using recombinant means. In some examples, V H is the heavy chain constant domain (C H ) Not connected to 1 and / or V L is the light chain constant domain (C L ) is not linked. An example Fv containing a polypeptide or protein is a Fab fragment, Fab' fragment, F(ab') fragment, scFv, diabody, triabody, tetrabody or higher-order complex, or a constant region or its domain, for example, C H 2 or C H The Fab fragment comprises three domains, for example, any of the aforementioned linked to a minibody. The Fab fragment consists of a monovalent antigen-binding fragment of immunoglobulin and can be produced by digesting the entire antibody with the enzyme papain to produce a fragment consisting of an intact light chain and part of the heavy chain, or by using recombinant means. The Fab fragment of an antibody is obtained by treating the entire antibody with pepsin and then reducing it to obtain an intact light chain and V HIt can be obtained by obtaining a molecule consisting of a portion of a heavy chain containing a single constant domain. Two Fab' fragments are obtained for each antibody treated in this manner. Fab' fragments can also be produced by recombinant means. The "F(ab')2 fragment" of an antibody consists of a dimer of two Fab' fragments held together by two disulfide bonds and is obtained by treating the entire antibody molecule with the enzyme pepsin without subsequent reduction. The "Fab2" fragment can be obtained, for example, from a leucine zipper or C H This recombinant fragment contains two Fab fragments linked using three domains. "Single-chain Fv" or "scFv" is a recombinant molecule containing an antibody variable region fragment (Fv), where the variable regions of the light chain and heavy chain are covalently linked by a suitable flexible polypeptide linker.
[0121] As used herein, the term “binding” with respect to the interaction between a compound or its antigen-binding site and an antigen means that the interaction depends on the presence of a specific structure on the antigen (e.g., an antigenic determinant or epitope). For example, antibodies generally recognize and bind to specific protein structures, rather than proteins themselves. When an antibody binds to epitope “A”, in a reaction involving a protein labeled “A”, the presence of a molecule containing epitope “A” (or free, unlabeled “A”) reduces the amount of labeled “A” bound to the antibody.
[0122] Where used herein, the terms “specifically binds” or “binds specifically” should be interpreted as meaning that the compounds of this disclosure react or associate more frequently, more rapidly, for longer periods and / or with higher affinity to a particular antigen or cell that expresses the same antigen or cell as an alternative antigen or cell. For example, the compounds bind to CD131 with substantially higher affinity (e.g., 20-fold or 40-fold or 60-fold or 80-fold to 100-fold or 150-fold or 200-fold) than they bind to antigens commonly recognized by other cytokine receptors or multireactive native antibodies (i.e., naturally occurring antibodies known to bind to a variety of naturally occurring antigens found in humans). Generally, though not always, references to binding should be understood to mean specific binding, and each term should be understood to provide explicit support for the others.
[0123] A protein or antibody has a K for another polypeptide. D A dissociation constant (K) smaller than D When binding to a polypeptide, it can be considered that the protein or antibody "preferentially binds" to the polypeptide. For example, when a protein or antibody binds to another polypeptide, the K of the protein or antibody D The affinity is at least approximately 20 times, 40 times, 60 times, 80 times, 100 times, 120 times, 140 times, or 160 times greater than (i.e., K D When binding to a polypeptide using ), it is considered to bind preferentially to the polypeptide.
[0124] For the purpose of clarification, and as will be obvious to those skilled in the art based on the exemplary subject matter herein, references to “affinity” herein refer to the K of a protein or antibody. D This is a reference to...
[0125] For the purpose of clarification, and as will be apparent to those skilled in the art based on the description herein, "K less than or equal to XnM" D The reference to "K DIt will be understood that the value of is equal to XnM, or that the value is lower. As a person skilled in the art will understand, K D A lower number corresponds to a higher (i.e., stronger) affinity; that is, an affinity of 2nM is stronger than an affinity of 3nM.
[0126] "At least about ~ IC 50 " is IC 50 However, the value greater than or equal to the listed value (i.e., IC 50 The number listed when the value is low is, that is, 2nM IC 50 However, 3nM IC 50 It will be understood to mean something greater than X. In other words, this term means "IC less than or equal to X". 50 This could be the case, where X is one of the values listed herein.
[0127] As used herein, the term “epitope” (synonym “antigenic determinant”) should be understood to mean the region of CD131 to which a protein, including the antigen-binding site of an antibody, binds. This term is not necessarily limited to the specific residues or structures that the protein contacts. For example, the term includes regions that a protein and / or 5-10, 2-5, or 1-3 amino acids contact. In some examples, an epitope includes a series of discontinuous amino acids that are located close to each other when CD131 is folded, i.e., a “conformational epitope.” Those skilled in the art will also recognize that the term “epitope” is not limited to peptides or polypeptides. For example, the term “epitope” includes chemically active surface classifications of molecules, such as sugar side chains, phosphoryl side chains, or sulfonyl side chains, which in certain examples may have specific three-dimensional structural properties and / or specific charge properties.
[0128] The term “competitively inhibiting” should be understood to mean that the protein (or its antigen-binding site) of this disclosure reduces or prevents the binding of the enumerated antibody or protein to CD131. This may be due to the protein (or antigen-binding site) and antibody binding to the same or overlapping epitopes. From the above, it becomes clear that the protein does not need to completely inhibit antibody binding, but rather needs to reduce binding by a statistically significant amount, e.g., at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. Preferably, the protein reduces antibody binding by at least about 30%, more preferably at least about 50%, more preferably at least about 70%, still more preferably at least about 75%, even more preferably at least about 80% or 85%, and even more preferably at least about 90%. Methods for determining competitive inhibition of binding are known in the art and / or described herein. For example, an antibody is exposed to CD131 either in the presence or absence of the protein. If fewer antibodies bind in the presence of a protein than in the absence of the protein, it is thought that the protein competitively inhibits antibody binding. In one example, the competitive inhibition is not due to steric hindrance.
[0129] In the context of two epitopes, "duplication" means that the two epitopes share a sufficient number of amino acid residues to allow a protein (or its antigen-binding site) that binds to one epitope to competitively inhibit the binding of a protein (or its antigen-binding site) that binds to the other epitope. For example, "duplication" epitopes share at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 20 amino acids.
[0130] inflammatory skin conditions The methods described herein can be used to treat inflammatory skin conditions, also referred to herein and elsewhere as “inflammatory skin disease” or “inflammatory skin disorder.” In some cases, the inflammation is non-infectious; for example, the inflammation is not associated with or caused by an infectious agent. The symptoms of an inflammatory skin disease or skin lesion may occur at a single site (location) of the subject or at multiple sites. In some cases, both one or more inflammatory skin conditions and one or more skin lesions may occur on the subject in any continuous section of skin or membrane, or at separate sites on the individual.
[0131] Inflammatory skin conditions are typically characterized by, for example, redness, itching, dryness, roughness, flaking, inflammation, and irritated skin, and the skin may also present with blisters, scaly plaques, etc. In some cases, the inflammatory skin condition is acute and generally resolves within days or weeks even without treatment, and the compositions and methods of the Disclosure improve the symptoms (e.g., itching, redness, etc.) and / or accelerate the disappearance of symptoms while the disease is resolving. Alternatively, in some cases, inflammatory skin diseases / disorders are chronic, and symptoms persist for weeks, months, years, or indefinitely, for example, without treatment or with conventional treatment. Use of the methods of the Disclosure improves (alleviates) the symptoms of chronic skin inflammation (e.g., relief of itching, redness, skin cracking and peeling, acceleration of healing of skin lesions, etc.) while the disease persists and / or partially or completely cures (completely or almost completely eliminates) the symptoms that would otherwise be present.
[0132] "Inflammatory skin conditions" are intended to encompass diseases and conditions caused by exposure to specific, known, or identifiable pathogens, as well as diseases / conditions whose causes are not clearly defined, such as immune disorders or dysfunctions (e.g., autoimmune reactions), stress, unidentified allergies, genetic predispositions, and / or diseases / conditions resulting from multiple factors. "Inflammatory skin conditions" are intended to encompass diseases and conditions that may have not only inflammation of the skin but also one or more other symptoms associated with it.
[0133] Inflammatory skin conditions (especially chronic inflammatory skin diseases) include, but are not limited to, hypersensitivity, autoimmune diseases (including autoimmune vesicular diseases), allergic diseases and reactions, neutrophilic skin diseases, atopic diseases, autoinflammatory diseases, antibody-mediated diseases and / or cell-mediated diseases (e.g., T-cells).
[0134] Atopic dermatitis Atopic dermatitis (AD, synonyms: neurodermatitis, atopic eczema, Benier's prurigo, endogenous eczema) is an inflammatory, chronically relapsing, non-contagious, and severely pruritic skin disorder characterized by epidermal inflammation, itching, dry skin (with fine scales), and exudation (acute lesions). It has a prevalence of 2-3% in the adult population and up to 20% in the child population, and is one of the most common skin diseases, with increasing prevalence in Western countries over the past 30 years. AD typically follows a relapsing course and is associated with elevated serum immunoglobulin (IgE) levels. In this regard, one of the major features of AD is elevated total serum IgE levels, and several IgE-targeting therapies, such as omalizumab, have been developed. Current understanding suggests that the pathogenesis of AD is the product of complex interactions between various susceptibility genes, host environment, infectious agents, skin barrier dysfunction, and immunological responses. In most cases, there is a positive family history of atopic diseases such as asthmatic bronchitis, allergic rhinitis, allergic conjunctivitis, and / or atopic dermatitis. These diseases are also often associated with the development of AD in the subjects.
[0135] The diagnosis of Alzheimer's disease (AD) is made clinically, based on historical features, morphology, distribution of skin lesions, and associated clinical signs. Various groups have developed formal criteria to aid in classification. One of the best-known diagnostic criteria is the Hanifin and Rajka criteria of 1980, which require meeting three of four major criteria and three of 23 minor criteria to make a diagnosis. The most common sites for eczematous rashes in AD are the face, neck, and flexor folds of the limbs. While preferred sites exist, skin lesions appear without clear boundaries and can involve virtually any part of the body—even the entire epidermis (erythroderma). The clinical pattern of AD also varies with age. The disease typically begins on the scalp and then spreads to the face and extensor surfaces of the arms and legs in infants, sometimes showing extensive exudation and crusting. Subsequently, the typical dominant pattern develops with eczematous complications of the flexor folds, neck, and hands. This involves dry skin and impaired skin barrier function, reflected by increased transcutaneous water loss, including in non-lesional skin, and increased irritant skin responses. Lichenification is a result of scratching and rubbing. Most frequently occurring in adults, this can result in the pruritic form of AD, primarily with exacerbated nodular lesions. Exacerbation often begins as increased itching without visible skin lesions. This is then followed by erythema, papules, and infiltration in acute skin lesions. Chronic AD skin lesions undergo tissue remodeling caused by chronic inflammation.
[0136] Compared to normal or unaffected skin of patients with atopic dermatitis, acute skin lesions of atopic dermatitis have significantly higher numbers of IL-4, IL-5, and IL-13 mRNA-expressing cells. Dendritic cells in the lesional and non-lesional skin of patients with the disease possess IgE molecules and, along with mast cells, contribute to the development of a mixed lymphocyte infiltration reaction including a subset of Th2 and T cells expressing IL-4 and IL-13 mRNA. After an initial phase mainly involving IL-4-producing Th2 cells, a subsequent phase characterized by IFN-γ-producing Th2 cells is thought to begin. This switch is thought to be initiated by local production of IL-12 from infiltration into eosinophils and / or dendritic cells. Activated T cells expressing Fas ligand have also been shown to induce apoptosis of keratinocytes, which contribute to the spongy state found in acute AD.
[0137] In the case of atopic dermatitis, there are currently no available treatments. Management includes disease-appropriate therapy combining adjuvant therapy (use of emollients) and anti-inflammatory measurements. In very severe cases, systemic treatment with drugs (e.g., systemic glucocorticoids, cyclosporine) or ultraviolet light may be indicated for a limited period, but topical glucocorticoids are the mainstay of treatment for AD and their use is well established. However, there are considerable safety concerns associated with their use, particularly when they are applied sequentially and / or in younger patients who are more sensitive to the side effects of glucocorticoids, including topical skin side effects (e.g., skin atrophy, telangiectasia, hypopigmentation) or systemic effects (hypothalamic-pituitary-adrenal axis (HPA) axis suppression, growth retardation, Cushing's syndrome).
[0138] Allergic contact dermatitis Allergic contact dermatitis (ACD) is considered a classic example of a type IV hypersensitivity reaction. Unlike AD, ACD is a form of contact dermatitis, meaning it develops as a result of heterologous chemicals penetrating the skin, chemically reacting with proteins, and ultimately leading to a hapten-specific T-cell-mediated immune response. Therefore, unlike AD, ACD is not associated with elevated IgE levels and is an exception in the use of the designation "allergy." The allergic signs and symptoms characteristic of ACD occur due to its clearly defined focal immune response: redness, edema, warmth, and itching of the skin. Diagnosis is confirmed by a diagnostic patch test, a clinically useful test that repeats the catalytic phase of ACD. The afferent phase of this disease develops gradually over time as a result of repeated, low-grade exposure of the patient to harmful chemicals.
[0139] ACD is a distinct disease entity with a clearly defined mechanism of initiation, amplification, plateau phase, and disease degradation. However, most environmental factors are too large to penetrate the skin through the stratum corneum, while some have molecular weights low enough to cross this barrier. These molecules can originate from naturally occurring substances such as urushiol found in poison ivy resin, synthetic compounds, and heavy metal ions. These compounds are often considered haptens and therefore cannot cause allergic reactions on their own. For a sensitization reaction to occur, the hapten must interact with endogenous compounds (i.e., proteins) in the skin. Such a sensitization reaction has been called the immune recognition of "altered self." That is, the chemical modification of a self molecule by a heterobiological hapten makes such a self molecule antigenic in that this newly generated antigen (hapten-modified self molecule) can trigger a specific immune response.
[0140] The mechanism of ACD involves a complex cascade of immune-mediated processes consisting of two distinct stages in response to exposure to environmental chemicals: 1) the induction stage (also known as the afferent or primary stage), and 2) the triggering stage (also known as the centrifugal or secondary stage).
[0141] During the induction phase of ACD, haptens applied to the skin interact with cellular proteins to form hapten-protein complexes, which are antigenic portions recognized by the immune system. These complexes are engulfed by antigen-presenting cells, such as dendritic cells, and presented in association with MHC class II. This activates antigen-specific T cells that proliferate into memory T cells. Furthermore, NKT cells are activated, leading to the release of cytokines including IL-2, TNF-α, and IL-4. In the presence of IL-4 and antigens, B cells are also activated and release circulating IgM.
[0142] During the induction phase, IgM interacts with hapten-protein complexes to induce complement activation, leading to the release of various inflammatory and chemodirectional factors from mast cells and endothelial cells. Thus, antigen-specific CD8+ T cells migrate to the hapten application site, interact with local antigen-presenting cells, and result in the clinical manifestation of ACD. The resulting mixed lymphocyte infiltration is a consequence of inflammatory cytokines, as well as cell-mediated cytotoxicity. Apart from forced antigen avoidance, topical glucocorticoids are central to the treatment of allergic contact dermatitis, and their use is well established. However, there are considerable safety concerns associated with their use, particularly when they are applied to patients who are sensitive to the side effects of glucocorticoids (due to their young age), including topical skin side effects (e.g., skin atrophy, telangiectasia, decreased pigmentation) or systemic effects (HPA axis suppression, growth retardation, Cushing's syndrome).
[0143] psoriasis In some cases, the diseases / conditions treated are psoriasis, including plaque psoriasis, droplet psoriasis, pustular psoriasis, nail psoriasis, photosensitive psoriasis, and erythrodermal psoriasis. Psoriasis is generally recognized as an autoimmune disorder and may be caused by factors such as infections (e.g., streptococcal pharyngitis or thrush), stress, skin injury (cuts, scrapes, insect bites, severe sunburn), certain medications (including lithium, antimalarial drugs, quinidine, and indomethacin), or may be associated with other autoimmune conditions such as type 2 diabetes, cardiovascular disease, hypertension, Crohn's disease, high cholesterol, depression, and ulcerative colitis. Psoriasis resulting from any of these causes, or any other or unknown causes, may be treated by the formulations and methods described herein.
[0144] In some cases, a person is defined as having psoriasis if they exhibit any of the following: 1) inflamed skin lesions covered with silvery-white scales (plaque psoriasis or psoriasis vulgaris); 2) small red dots appearing on the torso, arms, or legs (abdominal psoriasis); 3) smooth, non-scaly inflamed lesions on curved surfaces of the skin (reverse psoriasis); 4) widespread redness and peeling of fine scales with or without itching and swelling (erythrocytic psoriasis); 5) vesicular lesions (pustular psoriasis); 6) inflamed scalp lesions covered with silvery-white scales (scalp psoriasis); 7) pitted nails with or without yellowing, crushed nails, or inflammation and detachment from the nail bed.
[0145] antibody In one example, the compound described herein, in any example, is a protein containing an antigen-binding site of an antibody. In some examples, the compound that binds to CD131 is an antibody.
[0146] Methods for generating antibodies are known in the art and / or described in Harlow and Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, (1988). Generally, such methods involve the administration of CD131 or its region (e.g., extracellular domain) or its immunogenic fragment or epitope, or cells expressing and displaying it (i.e., immunogen), formulated with any suitable or desired carrier, adjuvant, or pharmaceutically acceptable excipient, to non-human animals, such as mice, chickens, rats, rabbits, guinea pigs, dogs, horses, goats, or pigs. The immunogen may be administered intranasally, intramuscularly, subcutaneously, intravenously, intradermally, intraperitoneally, or by other known routes.
[0147] Monoclonal antibodies are one exemplary form of antibodies contemplated in this disclosure. The terms “monoclonal antibody” or “mAb” refer to a homogeneous population of antibodies capable of binding to the same antigen, for example, the same epitope within the antigen. The terms are not intended to be limited in terms of the source of the antibody or the method by which it is produced.
[0148] For mAb production, one of several known techniques may be used, such as the procedure exemplified in US4196265 or Harlow and Lane (1988) (see above).
[0149] Alternatively, ABL-MYC technology (NeoClone, Madison WI 53713, USA) can be used to produce MAb-secreting cell lines (as described, for example, in Largaespada et al, J.Immunol.Methods. 197:85-95, 1996).
[0150] Antibodies can also be produced or isolated by screening display libraries, such as phage display libraries, as described, for example, in US6300064 and / or US5885793. For example, the inventors isolated fully human antibodies from phage display libraries.
[0151] The antibodies in this disclosure may be synthetic antibodies. For example, the antibodies may be chimeric antibodies, humanized antibodies, human antibodies, or deimmunized antibodies.
[0152] For example, the antibodies described herein are chimeric antibodies. The term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain originates from a particular species (e.g., mice) or is identical or homologous to a corresponding sequence in an antibody belonging to a particular antibody class or subclass, while the rest of the chain originates from another species (e.g., primates such as humans) or is identical or homologous to a corresponding sequence in an antibody belonging to another antibody class or subclass. Methods for producing chimeric antibodies are described, for example, in US4816567 and US5807715.
[0153] The antibody disclosed herein may be a humanized antibody or a human antibody.
[0154] The term "humanized antibody" should be understood to refer to a subclass of chimeric antibodies that have an antigen-binding site or variable region derived from an antibody of a non-human species, and the remaining antibody structure is based on the structure and / or sequence of a human antibody. In humanized antibodies, the antigen-binding site generally includes a complementation-determining region (CDR) from the non-human antibody conjugated to an appropriate FR within the variable region of the human antibody, and the remaining region from the human antibody. The antigen-binding site may be wild-type (i.e., identical to that of the non-human antibody) or may be modified by one or more amino acid substitutions. In some cases, the FR residue of the human antibody is replaced by a corresponding non-human residue.
[0155] Methods for humanizing non-human antibodies or portions thereof (e.g., variable regions) are known in the art. Humanization can be carried out according to the methods of US5225539 or US5585089. Other methods for humanizing antibodies are not excluded.
[0156] As used herein, the term "human antibody" refers to a variable region (e.g., V H , V L ), and antibodies derived from sequences found in human cells, such as human germ cells or somatic cells, or having a corresponding, optionally selected region.
[0157] Examples of human antibodies described herein include 9A2-VR24.29 (also referred to as "CSL311") as described in WO2017 / 088028, and BION-1 as described in Sun et al. (1999) Blood 94:1943-1951, and / or proteins or derivatives thereof containing their variable region. These human antibodies offer the advantage of reduced immunogenicity in humans compared to non-human antibodies.
[0158] In one example, an antibody is a multispecific antibody. For instance, a compound that binds to CD131 may be a protein containing an antigen-binding site that binds to CD131 and a further antigen-binding site that binds to a different antigen. Therefore, in some examples, an antibody is a bispecific antibody.
[0159] Proteins containing antibody-binding domains Single-domain antibody In some examples, the compounds of this disclosure are single-domain antibodies (used interchangeably with the terms “domain antibody,” “dAb,” or “nanobody”) or proteins containing them. A single-domain antibody is an antibody fragment consisting of a single monomeric variable antibody domain. Like the whole antibody, it can selectively bind to a particular antigen. With a molecular weight of only 12–15 kDa, single-domain antibodies are much smaller than typical antibodies (150–160 kDa) consisting of two heavy protein chains and two light chains, and even smaller than Fab fragments (about 50 kDa, one light chain and half heavy chains) and single-chain variable fragments (about 25 kDa, two variable domains, one from the light chain and the other from the heavy chain). In certain examples, a single-domain antibody is a human single-domain antibody (see Domantis, Inc., Waltham, MA; see, e.g., US6248516).
[0160] In some cases, single-domain antibodies are V H This is an H fragment. H The H fragment is the variable domain (V) of the camelid heavy chain antibody described below. H ) consists of.
[0161] In some cases, single-domain antibodies are V NAR It is a fragment. V NAR The fragment is the variable domain (V) of a heavy chain antibody derived from cartilaginous fish, as described below. H ) consists of.
[0162] Diabody, Triabody, Tetrabody In some examples, the proteins of this disclosure are or include diabodies, triabodies, tetrabodies, or higher-dimensional protein complexes, such as those described in WO98 / 044001 and / or WO94 / 007921.
[0163] Single chain Fv (scFv) Those skilled in the art will see that scFv is V in a single polypeptide chain. H and V L Region, and V H and VL It includes a polypeptide linker between the scFv, which allows the scFv to form the desired structure for antigen binding (i.e., the V of a single polypeptide chain). H and V L They will recognize that they associate with each other to form Fv. For example, the linker contains more than 12 amino acid residues, and (Gly4Ser)3 is one of the more preferred linkers for scFv.
[0164] Heavy chain antibodies Heavy chain antibodies are structurally different from many other forms of antibodies, as they contain a heavy chain but lack a light chain. Therefore, these antibodies are also called "heavy chain only antibodies." Heavy chain antibodies are found, for example, in camelids and cartilaginous fish (also known as IgNARs).
[0165] A general description of heavy chain antibodies derived from camelids and their variable regions, and methods for their production and / or isolation and / or use, can be found, in particular, in the following references WO94 / 04678, WO97 / 49805 and WO97 / 49805.
[0166] A general description of heavy chain antibodies derived from cartilaginous fish and their variable regions, as well as methods for their production and / or isolation and / or use, can be found, in particular, in WO2005 / 118629.
[0167] Other antibodies and antibody fragments This disclosure also relates to other antibodies and antibody fragments, for example, (i) The “key and hole” bispecific protein described in US5,731,168, (ii) For example, heterocoupled proteins as described in US4,676,980, (iii) For example, heterocoupled proteins produced using chemical crosslinking agents described in US4,676,980, and (iv) Conceive Fab3 (for example, as described in EP1993 / 0302894).
[0168] V-like protein An example of the compounds disclosed herein is the T cell receptor. The T cell receptor has two V domains that bind to a structure similar to that of the antibody's Fv module. Novotny et al., Proc Natl Acad Sci USA 88:8646-8650, 1991 describes how the two V domains (referred to as α and β) of the T cell receptor can be fused and expressed as a single-chain polypeptide, and further, how surface residues can be altered to reduce hydrophobicity directly similar to that of the antibody scFv. Other publications describing the production of single-chain or multimeric T cell receptors containing two V-α and V-β domains include WO1999 / 045110 and WO2011 / 107595.
[0169] Other non-antibody proteins containing antigen-binding domains include proteins that generally have a monomeric V-like domain. Examples of proteins containing such V-like domains include CTLA-4, CD28, and ICOS. Further disclosures of proteins containing such V-like domains are included in WO1999 / 045110.
[0170] Adnectin In one example, the compound of this disclosure is adonectin. Adonectin is a 10th fibronectin type III of human fibronectin in which the loop region is modified to confer antigen binding. 10 Based on the Fn3 domain. For example, 10 By manipulating the three loops at one end of the β-sandwich of the Fn3 domain, adnectin can be made to specifically recognize antigens. For further details, see US2008 / 0139791 or WO2005 / 056764.
[0171] Anticharin In a further example, the compound of this disclosure is antikalin. Antikalin is derived from lipocalin, a family of extracellular proteins that transport small hydrophobic molecules such as steroids, bilines, retinoids, and lipids. Lipocalin has a rigid β-sheet secondary structure with multiple loops at the open end of a conical structure that can be manipulated to bind to antigens. Such manipulated lipocalin is known as antikalin. For a further description of antikalin, see US7250297B1 or US2007 / 0224633.
[0172] Affibody In a further example, the compounds of this disclosure are affibodies. Affibodies are scaffolds derived from the Z domain (antigen-binding domain) of Staphylococcus aureus protein A, which can be engineered to bind to an antigen. The Z domain consists of a 3-helical bundle of approximately 58 amino acids. Libraries have been generated by randomization of surface residues. See EP1641818 for further details.
[0173] Abimar In a further example, the compounds of this disclosure are avimers. Avimers are multi-domain proteins derived from the A-domain scaffold family. The native domain of approximately 35 amino acids employs a defined disulfide bond structure. Diversity is generated by the shuffling of the natural variations exhibited by the A-domain family. For further details, see WO2002 / 088171.
[0174] DARPin In a further example, the compounds of this disclosure are engineered ankyrin repeat proteins (DARPin). DARPin is derived from ankyrin, a family of proteins that mediate the binding of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33-residue motif consisting of two α-helices and β-turns. They can be manipulated to bind to different target antigens by randomizing the residues in the first α-helix and the β-turns of each repeat. Their binding interfaces can be increased by increasing the number of modules (affinity maturation method). For further details, see US20040132028.
[0175] Deimmune proteins This disclosure also intends to provide deimmunizing antibodies or proteins. Deimmunizing antibodies and proteins have one or more epitopes, for example, a B cell epitope or a removed (i.e., mutated) T cell epitope, thereby reducing the likelihood that a mammal will elevate its immune response to the antibody or protein. Methods for producing deimmunizing antibodies and proteins are known in the art and are described, for example, in WO2000 / 34317, WO2004 / 108158 and WO2004 / 064724.
[0176] Methods for introducing suitable mutations and for expressing and assaying the resulting proteins will be obvious to those skilled in the art based on the description herein.
[0177] Mutations in proteins This disclosure also intends to describe variants of the proteins described herein. For example, such a variant protein contains one or more conserved amino acid substitutions compared to the sequences described herein. In some examples, the protein contains 30 or fewer, or 20 or fewer, or 10 or fewer, for example, 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 conserved amino acid substitutions. A “conserved amino acid substitution” is one in which an amino acid residue is replaced by an amino acid residue with a similar side chain and / or hydrophilic and / or hydrophilic.
[0178] In one example, a mutant protein may have only one, two, three, four, five, or six conservation amino acid changes compared to a naturally occurring protein, or fewer. Details of conservation amino acid changes are provided below. As those skilled in the art will recognize, for example, from the disclosure herein, such minor changes can be reasonably predicted not to alter the activity of the protein.
[0179] The families of amino acid residues having similar side chains include, as defined in the art, basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), non-charged side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0180] This disclosure also intends to involve non-conserved amino acid changes (e.g., substitutions) in CDRs, such as CDR3, of the proteins of this disclosure. For example, the protein contains, for example, fewer than 6, 5, 4, 3, 2, or 1 non-conserved amino acid substitution in CDR3.
[0181] This disclosure also intends to include one or more insertions or deletions compared to the sequences described herein. In some examples, the protein may include 10 or fewer insertions and / or deletions, for example, 9, 8, 7, 6, 5, 4, 3, or 2.
[0182] Steady-state region This disclosure encompasses proteins and / or antibodies described herein, including the constant region of an antibody, which includes an antigen-binding fragment of the antibody fused to Fc.
[0183] The sequences of the constant regions useful for the production of the proteins of the present disclosure can be obtained from several different sources. In some examples, the constant region of the protein or a portion thereof is derived from a human antibody. The constant region or a portion thereof can be derived from any antibody class including IgM, IgG, IgD, IgA, and IgE, and any antibody isotype including IgG1, IgG2, IgG3, and IgG4. In one example, the constant region is the human isotype IgG4 or a stabilized IgG4 constant region.
[0184] In one example, the Fc region of the constant region has a reduced ability to induce effector functions compared to, for example, a native or wild-type human IgG1 or IgG3 Fc region. In one example, the effector functions are antibody-dependent cell-mediated cytotoxicity (ADCC) and / or antibody-dependent cell-mediated phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC). Methods for assessing the level of effector function of an Fc region containing a protein are known in the art and / or described herein.
[0185] In one example, the Fc region is an IgG4 Fc region (i.e., from an IgG4 constant region), for example, a human IgG4 Fc region. Suitable sequences of the IgG4 Fc region will be apparent to those skilled in the art and / or available in publicly accessible databases (e.g., available from the National Center for Biotechnology Information).
[0186] In one example, the constant region is the stabilized IgG4 constant region. The term “stabilized IgG4 constant region” would be understood to mean an IgG4 constant region modified to reduce the tendency to undergo Fab arm exchange, or to undergo Fab arm exchange or to reduce the tendency to form half-antibodies. “Fab arm exchange” refers to a type of protein modification of human IgG4, where the IgG4 heavy chain and binding light chain (half-molecule) are exchanged for a heavy / light chain pair from another IgG4 molecule. Thus, an IgG4 molecule can acquire two different Fab arms that recognize two different antigens (resulting in a bispecific molecule). Fab arm exchange occurs spontaneously in vivo and can be induced in vitro by purified blood cells or by reducing agents such as reduced glutathione. “Half-antibodies” are formed when an IgG4 antibody dissociates to form two molecules, each containing a single heavy chain and a single light chain.
[0187] In one example, the stabilized IgG4 constant region contains proline at position 241 of the hinge region according to Kabat's system (Kabat et al., Sequences of Proteins of Immunological Interest, Washington DC, United States Department of Health and Human Services, 1987 and / or 1991). This position corresponds to position 228 of the hinge region according to the EU numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, Washington DC, United States Department of Health and Human Services, 2001 and Edelman et al., Proc. Natl. Acad. USA, 63, 78-85, 1969). In human IgG4, this residue is generally serine. Following the serine substitution for proline, the IgG4 hinge region contains the sequence CPPC. In this regard, those skilled in the art will recognize that the “hinge region” is the proline-rich portion of the antibody heavy chain constant region that links the Fc and Fab regions, which confer mobility to the two Fab arms of the antibody. The hinge region contains cysteine residues involved in the inter-heavy-chain disulfide bond. This is generally defined, according to Kabat's numbering system, as the extension from Glu226 to Pro243 in human IgG1. Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing the first and last cysteine residues that form the inter-heavy-chain disulfide (SS) bond at the same positions (see, for example, WO2010 / 080538).
[0188] Further examples of stabilized IgG4 antibodies are those in which the arginine at position 409 (according to the EU numbering system) in the heavy chain constant region of human IgG4 is replaced with lysine, threonine, methionine, or leucine (as described, e.g., in WO2006 / 033386). The Fc region of the constant region may additionally or alternatively contain a residue selected from the group consisting of alanine, valine, glycine, isoleucine, and leucine at the position corresponding to 405 (according to the EU numbering system). Optionally, the hinge region may contain proline (i.e., a CPPC sequence) at position 241 (as described above).
[0189] In another example, the Fc region is a region modified to have reduced effector function, i.e., a “non-immunostimulatory Fc region.” For example, the Fc region is an IgG1 Fc region containing substitutions at one or more positions selected from the group consisting of 268, 309, 330, and 331. In yet another example, the Fc region is an IgG1 Fc region containing one or more deletions of the following modifications E233P, L234V, L235A, and G236, and / or one or more of the following modifications A327G, A330S, and P331S (Armour et al., Eur J Immunol. 29:2613-2624, 1999; Shields et al., J Biol Chem. 276(9):6591-604, 2001). Further examples of non-immunostimulatory Fc regions are described, for example, in Dall'Acqua et al., J Immunol. 177:1129-1138 2006, and / or Hezareh J Virol; 75:12161-12168, 2001).
[0190] In another example, the Fc region is, for example, at least one C derived from an IgG4 antibody. H 2 domains and at least one C derived from the IgG1 antibody HThe Fc region is a chimeric region containing three domains, the Fc region containing substitutions at one or more amino acid positions selected from the group consisting of 240, 262, 264, 266, 297, 299, 307, 309, 323, 399, 409, and 427 (EU numbering) (e.g., as described in WO2010 / 085682). Exemplary substitutions include 240F, 262L, 264T, 266F, 297Q, 299A, 299K, 307P, 309K, 309M, 309P, 323F, 399S, and 427F.
[0191] Additional modifications This disclosure also intends to involve further modifications to the antibodies or proteins described herein.
[0192] For example, an antibody contains one or more amino acid substitutions that increase the half-life of a protein. For example, an antibody contains an Fc region containing one or more amino acid substitutions that increase the affinity of the Fc region to the fetal Fc receptor (FcRn). For example, the Fc region increased its affinity for FcRn at lower pH, e.g., around pH 6.0, to facilitate Fc / FcRn binding in endosomes. In one example, the Fc region increased its affinity for FcRn at around pH 6 compared to its affinity at around pH 7.4, which facilitates the re-release of Fc into the bloodstream after cell recycling. These amino acid substitutions are useful in extending the half-life of a protein by reducing its clearance from the blood.
[0193] Examples of amino acid substitutions include T250Q and / or M428L or T252A, T254S and T266F or M252Y, S254T and T256E or H433K and N434F according to the EU numbering system. Additional or alternative amino acid substitutions are described, for example, in US2007 / 0135620 or US7083784.
[0194] The protein may be a fusion protein. Therefore, in one example, the protein further comprises albumin, a functional fragment thereof, or a variant thereof. In one example, the albumin, its functional fragment thereof, or variant thereof is serum albumin, such as human serum albumin. In one example, the albumin, its functional fragment thereof, or variant thereof includes one or more amino acid substitutions, deletions, or insertions, e.g., five or fewer, four or fewer, three or fewer, two or fewer, or one or fewer substitutions. Amino acid substitutions suitable for use in this disclosure will be obvious to those skilled in the art and include naturally occurring substitutions as well as manipulated substitutions, such as those described in WO2011 / 051489, WO2014 / 072481, WO2011 / 103076, WO2012 / 112188, WO2013 / 075066, WO2015 / 063611 and WO2014 / 179657.
[0195] In one example, the protein of this disclosure further comprises a soluble complement receptor or a functional fragment or variant thereof. In another example, the protein further comprises a complement inhibitor.
[0196] Protein production For example, the proteins described herein, according to any example, are produced by culturing a hybridoma under conditions sufficient to produce the protein, for example, as described herein and / or as known in the art.
[0197] Recombinant expression In another example, any protein described herein is recombinant.
[0198] In the case of recombinant proteins, the nucleic acid encoding it can be cloned into an expression construct or vector, which is then transfected into host cells such as E. coli cells, yeast cells, insect cells, or mammalian cells, e.g., monkey COS cells, Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, or, in other cases, myeloma cells that do not produce the protein. Exemplary cells used to express the protein are CHO cells, myeloma cells, or HEK cells. Molecular cloning techniques for achieving these objectives are known in the art and are described, for example, in Ausubel et al., (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including updates to date) or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989). A wide variety of cloning and in vitro amplification methods are suitable for constructing recombinant nucleic acids. Methods for producing recombinant antibodies are also known in the art; see, for example, US4816567 or US5530101.
[0199] After isolation, the nucleic acid is operably ligated and inserted into a promoter in an expression construct or expression vector for further cloning (DNA amplification) or for expression in a cell-free system or within cells.
[0200] As used herein, the term “promoter” should be taken in its broadest context and includes transcriptional regulatory sequences of genomic genes, including TATA boxes or initiator elements necessary for accurate transcription initiation, with or without additional regulatory elements (e.g., upstream activating sequences, transcription factor binding sites, enhancers, and silencers) that alter nucleic acid expression, for example, in response to development and / or external stimuli, or in a tissue-specific manner. In this context, the term “promoter” is also used to describe recombinant, synthetic, or fusion nucleic acids or derivatives that confer, activate, or enhance the expression of the nucleic acid to which it is operably linked. Exemplary promoters may contain additional copies of one or more specific regulatory elements to further enhance expression and / or alter the spatial and / or temporal expression of the nucleic acid.
[0201] As used herein, the term “operably linked to” means positioning a promoter relative to a nucleic acid such that the expression of the nucleic acid is controlled by the promoter.
[0202] Many vectors are available for intracellular expression. Vector components generally include, but are not limited to, one or more of the following: signal sequences, protein-coding sequences (e.g., derived from the information provided herein), enhancer elements, promoters, and transcription termination sequences. Those skilled in the art will recognize suitable sequences for protein expression. Exemplary signal sequences include prokaryotic secretory signals (e.g., pelB, alkaline phosphatase, penicillinase, Ipp, or thermostable enterotoxin II), yeast secretory signals (e.g., invertase reader, α-factor reader, or acid phosphatase reader), or mammalian secretory signals (e.g., herpes simplex gD signal).
[0203] Exemplary active promoters in mammalian cells include the cytomegalovirus early promoter (CMV-IE), human elongation factor 1-α promoter (EF1), micronuclear RNA promoters (U1a and U1b), α-myosin heavy chain promoter, Simian virus 40 promoter (SV40), Roussarcoma virus promoter (RSV), adenovirus major late promoter, β-actin promoter, CMV enhancer / β-actin promoter, or immunoglobulin promoters or hybrid regulatory elements including their active fragments. Examples of useful mammalian host cell lines include the CV1 monkey kidney cell line transformed with SV40 (COS-7, ATCC CRL1651), human embryonic kidney cells (293 or 293 cells subcloned for growth in suspension culture), baby hamster kidney cells (BHK, ATCC CCL10), or Chinese hamster ovary cells (CHO).
[0204] For example, typical promoters suitable for expression in yeast cells, such as yeast cells selected from the group including Pichia pastoris, Saccharomyces cerevisiae, and Schizosaccharomyces pombe, include, but are not limited to, the ADH1 promoter, GAL1 promoter, GAL4 promoter, CUP1 promoter, PHO5 promoter, nmt promoter, RPR1 promoter, or TEF1 promoter.
[0205] Means for introducing into cells a nucleic acid isolated for expression or an expression construct containing the same are known to those skilled in the art. The technique used for a given cell depends on known successful techniques. Means for introducing recombinant DNA into cells include, inter alia, microinjection, transfection mediated by DEAE-dextran, transfection mediated by liposomes (e.g., by using Lipofectamine (Gibco, MD, USA) and / or Cellfectin (Gibco, MD, USA)), PEG-mediated DNA uptake, electroporation, and particle bombardment such as by using tungsten or gold particles coated with DNA (Agracetus Inc., WI, USA).
[0206] Host cells used for producing proteins can be cultured in various media depending on the cell type used. Commercially available media such as Ham’s Fl0 (Sigma), Minimum Essential Medium ((MEM), (Sigma), RPMl-1640 (Sigma), Dulbecco’s Modified Eagle Medium (DMEM) Sigma), etc. are suitable for culturing mammalian cells. Media for culturing other cell types considered herein are known in the art.
[0207] Isolation of Protein Methods for isolating proteins are known in the art and / or described herein.
[0208] When the protein is secreted into the medium, the supernatant from such an expression system can first be concentrated using a commercially available protein concentration filter, e.g., an Amicon or Millipore Pellicon ultrafiltration unit. Protease inhibitors such as PMSF may be included in any of the foregoing steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of exogenous contaminants. Alternatively, or additionally, the supernatant can be filtered and / or separated from the cells expressing the protein, e.g., using continuous centrifugation.
[0209] Proteins prepared from cells can be purified using, for example, ion exchange, hydroxyapatite chromatography, hydrophobic interaction chromatography, gel electrophoresis, dialysis, affinity chromatography (e.g., protein A affinity chromatography or protein G chromatography), or any combination thereof. These methods are known in the art and are described, for example, in WO1999 / 57134 or in Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, (1988).
[0210] Those skilled in the art will also recognize that proteins can be modified to include tags for facilitating purification or detection, such as polyhistidine tags, such as hexahistidine tags, influenza virus hemagglutinin (HA) tags, simian virus 5 (V5) tags, flag tags, or glutathione S-transferase (GST) tags. The resulting proteins are purified using methods known in the art, such as affinity purification. For example, a protein containing a hexa-his tag is purified by contacting a sample containing the protein with nickel-nitrilotriacetic acid (Ni-NTA) that specifically binds to the hexa-his tag immobilized on a solid or semi-solid support, washing the sample to remove unbound proteins, and then eluting the bound proteins. Alternatively, or in addition, ligands or antibodies that bind to the tags are used in affinity purification methods.
[0211] Nucleic acid compounds that bind to CD131 For example, a compound that binds to CD131 is a nucleic acid aptamer (adaptive oligomer). An aptamer is a single-stranded oligonucleotide or oligonucleotide analog that can form a secondary and / or tertiary structure that provides the ability to bind to a specific target molecule, such as a protein or small molecule, such as CD131. Thus, an aptamer is an oligonucleotide analog to an antibody. Generally, aptamers contain about 15 to about 100 nucleotides, for example, about 15 to about 40 nucleotides, for example, about 20 to about 40 nucleotides, because oligonucleotides of this length range can be prepared by conventional techniques.
[0212] Aptamers can be isolated from or identified from an aptamer library. An aptamer library is produced, for example, by cloning random oligonucleotides into a vector (or, in the case of RNA aptamers, an expression vector), where the random sequences are adjacent to known sequences that provide PCR primer binding sites. Aptamers that provide the desired biological activity (e.g., those that specifically bind to CD131) are selected. Aptamers with increased activity are selected, for example, using SELEX (Systematic Expansion of Ligands by Exponential Increase). Preferred methods for preparing and / or screening aptamer libraries are described, for example, in Elloington and Szostak, Nature 346:818-22, 1990, US5270163, and / or US5475096.
[0213] Compound assay activity Binding to CD131 Methods for evaluating the binding of candidate compounds to proteins (e.g., CD131) are known in the art, for example, as described in Scopes (Protein purification: principles and practice, Third Edition, Springer Verlag, 1994). Such methods generally involve labeling the protein and bringing it into contact with the immobilized compound. After washing to remove nonspecific binding proteins, the amount of labeling and, consequently, the binding proteins are detected. Naturally, proteins can be immobilized and compounds can be labeled. Panning assays can also be used. Alternatively, or additionally, surface plasmon resonance assays can be used. The level of binding can also be conveniently determined using a biosensor.
[0214] Optionally, the dissociation constant (Kd) of a CD131 compound or its epitope is determined. The "Kd" or "Kd value" of a compound that binds to CD131 is measured, in one example, by an radiolabeled or fluorescently labeled CD131 binding assay. In this assay, the compound is equilibrated with the minimum concentration of labeled CD131 in the presence of a titration series of unlabeled CD131. After washing to remove unbound CD131, the amount of label is determined, which indicates the Kd of the protein.
[0215] In another example, Kd or Kd values are measured by using a surface plasmon resonance assay, for example, with a BIAcore surface plasmon resonance (BIAcore, Inc., Piscataway, NJ) having immobilized CD131 or a region thereof.
[0216] Epitope Mapping In another example, epitopes bound by the proteins described herein are mapped. The epitope mapping method will be obvious to those skilled in the art. For example, a series of duplicate peptides, e.g., peptides containing 10 to 15 amino acids, are prepared, spanning the CD131 sequence or region containing the epitope of interest. The protein is then brought into contact with each peptide and the peptide to which it binds. This allows for the determination of the peptide containing the epitope to which the protein binds. If multiple discontinuous peptides are bound to the protein, the protein may bind to a structural epitope.
[0217] Alternatively, or in addition, amino acid residues within CD131 can be mutated, for example, by alanine scan mutagenesis, determining mutations that reduce or prevent protein binding. Any mutation that reduces or prevents protein binding is likely to be located within an epitope bound by the protein.
[0218] Further methods are illustrated herein and include conjugating CD131 or a region thereof to the immobilized protein of this disclosure and digesting the resulting complex with a protease. The peptides remaining bound to the immobilized protein are isolated and their sequences are determined by analysis, for example, using mass spectrometry.
[0219] A further method includes converting hydrogen to deuterium in CD131 or its region and binding the resulting protein to the immobilized protein of this disclosure. The deuterium is then converted to hydrogen, CD131 or its region is isolated, digested enzymatically, and analyzed, for example by mass spectrometry, to identify the regions containing deuterium that would have been protected from conversion to hydrogen by the binding of the protein described herein.
[0220] Alternatively, the epitopes to which proteins bind can be determined by X-ray crystallography. For example, a complex is formed between the protein and CD131, and then crystallized. The resulting crystals are then subjected to X-ray diffraction analysis to determine the atomic coordinates of the amino acids in the complex. The epitopes contain the amino acids in CD131 that are in contact with the protein, according to the atomic coordinates determined by X-ray diffraction.
[0221] Determining competitive coupling Assays for determining proteins that competitively inhibit the binding of antibody 9A2-VR24.29 will be obvious to those skilled in the art. For example, 9A2-VR24.29 is conjugated to a detectable label, such as a fluorescent or radioactive label. The labeled antibody and test protein are then mixed and brought into contact with CD131 or its region (e.g., a polypeptide containing SEQ ID NO: 1 or 5) or a cell expressing it. The level of labeled 9A2-VR24.29 is then determined and compared to the level determined when the labeled antibody was brought into contact with CD131, the region, or the cell in the absence of the protein. If the level of labeled 9A2-VR24.29 decreases in the presence of the test protein compared to the absence of the protein, the protein is considered to competitively inhibit the binding of 9A2-VR24.29 to CD131.
[0222] Optionally, the test protein may be conjugated to a different label at 9A2-VR24.29. This alternative label allows for the detection of the level of binding of the test protein to CD131 or its region or to cells.
[0223] In another example, the protein is allowed to bind to CD131 or its region (e.g., a polypeptide containing SEQ ID NO: 1 or 5), or to cells expressing it, before contacting CD131, its region, or the cells with 9A2-VR24.29. A decrease in the amount of bound 9A2-VR24.29 in the presence of the protein, compared to the absence of the protein, indicates that the protein competitively inhibits the binding of 9A2-VR24.29 to CD131. The cross-assay can also be performed using a labeled protein, allowing 9A2-VR24.29 to bind to CD131 first. In this case, a decrease in the amount of labeled protein bound to CD131 in the presence of 9A2-VR24.29, compared to the absence of 9A2-VR24.29, indicates that the protein competitively inhibits the binding of 9A2-VR24.29 to CD131.
[0224] Any of the aforementioned assays can be performed, for example, using the ligand-binding region of CD131 to which CD131 and / or variants of SEQ ID NO: 1 or 5 and / or 9A2-VR24.29 are bound, as described herein.
[0225] Neutralization decision For example, compounds that bind to CD131 reduce or prevent the binding of IL-3, IL-5, and / or GM-CSF to CD131-containing receptors (e.g., IL-3R, IL-5R, and / or GM-CSF-R, respectively). These assays can be performed as competitive binding assays using labeled IL-3 / IL-5 / GM-CSF and / or labeled compounds. For example, cells expressing the relevant receptors are brought into contact with IL-3 / IL-5 / GM-CSF in or out of the presence of the CD131-binding compound, and the amount of binding label is detected. A decrease in the amount of binding label in the presence of the CD131-binding compound compared to the absence of the compound indicates that the compound reduces or prevents the binding of IL-3 / IL-5 / GM-CSF to CD131-containing receptors. IC can be determined by testing multiple concentrations of the compound. 50 It is possible to determine that CD131 or EC 50The concentration of a compound that reduces the amount of IL-3 / IL-5 / GM-CSF that binds to receptors containing the compound can be determined, i.e., the concentration of the protein that achieves 50% of the maximum inhibition of IL-3 / IL-5 / GM-CSF binding to CD131 achieved by the compound.
[0226] In a further example, CD131-binding compounds reduce or prevent IL-3 / IL-5 / GM-CSF-mediated proliferation of the leukemia cell line TF-1. For example, TF-1 cells are cultured without IL-3 / IL-5 / GM-CSF for a sufficient time to stop proliferation (e.g., 24-48 hours). The cells are then cultured in the presence of IL-3 / IL-5 / GM-CSF and various concentrations of CD131-binding compounds. Control cells are not in contact with the compounds (positive control) or IL-3 / IL-5 / GM-CSF (negative control). Cell proliferation is then performed using standard techniques, e.g., 3 The integration of H-thymidine is used for evaluation. CD131-binding compounds that reduce or prevent cell proliferation to levels below the positive control in the presence of IL-3 are thought to neutralize IL-3 signaling. IC is evaluated by testing multiple concentrations of CD131-binding compounds. 50 To decide.
[0227] In another example, CD131-binding compounds inhibit or prevent STAT-5 activation. For example, cells containing a β-lactamase reporter gene under the control of the interferon regulator 1 (irf1) response element in the presence of IL-3 and / or GM-CSF (e.g., TF-1 cells). Suitable cells are available from Life Technologies Corporation. The cells are also brought into contact with a suitable substrate (e.g., a negatively charged fluorescent β-lactamase substrate such as CCF2 or CCF4) to determine the change in the signal (e.g., fluorescence). A decrease in the change in the signal in a positive control (i.e., cells brought into contact with IL-3 and / or GM-CSF in the absence of the compound) indicates that the compound reduces or prevents IL-3 and / or GM-CSF-induced STAT-5 signaling.
[0228] In a further example, the CD131-binding compounds of this disclosure are immune cells. For example, the CD131-binding compounds reduce or inhibit the activation of isolated human neutrophils by GM-CSF, as determined by reducing or inhibiting the GM-CSF-induced increase in neutrophil cell size. For example, neutrophils (e.g., about 1 × 10⁶) 5 Cells are cultured for a suitable time (e.g., about 24 hours) in the presence of CD-131 binding protein and GM-CSF. Then, the cells are fixed (e.g., with formaldehyde) and analyzed for forward scattering using flow cytometry.
[0229] For example, CD131-binding compounds reduce or inhibit IL-3-induced IL-8 secretion by human basophils. For example, basophils (e.g., approximately 1 × 10⁻⁶) 5 Cells are cultured for a suitable time (e.g., 24 hours) in the presence of a CD131-binding compound and IL-3. IL-8 secretion is then evaluated using ELISA, as is available from R&D Systems, for example.
[0230] In further examples, CD131-binding compounds reduce or prevent IL-3-mediated survival or pDCs. For example, pDCs are cultured for a suitable time (e.g., 24 hours) in the presence of a CD131-binding compound and IL-3. Cell viability is then evaluated using standard methods, such as the ViaLight Plus Kit from Lonza.
[0231] In further examples, CD131-binding compounds reduce or prevent IL-5-mediated activation of human peripheral blood eosinophils, as determined by evaluating changes in forward scattering assessed by flow cytometry. For example, eosinophils (e.g., approximately 1 × 10⁻⁶) 5 Cells are cultured for a suitable time (e.g., about 24 hours) in the presence of a CD131-binding compound and IL-5. Then, the cells are fixed (e.g., with formaldehyde) and changes in forward scattering are evaluated using flow cytometry.
[0232] In a further example, the CD131-binding compounds of this disclosure reduce or prevent the survival of human peripheral blood eosinophils in the presence of IL-5 and / or GM-CSF and / or IL-3. For example, eosinophils (e.g., about 1 × 10⁻⁶) 4 Cells are cultured in the presence of a CD131-binding compound and IL-5 and / or GM-CSF and / or IL-3 for a suitable time (e.g., about 5 days) and in the presence of a cell count assessed using a standard method (e.g., ViaLight Plus Kit from Lonza).
[0233] In a further example, the CD131-binding compounds of this disclosure reduce or prevent IL-3-induced TNFα release from human mast cells. For example, human cultured mast cells (e.g., 10-week-old peripheral blood-derived cells) are cultured in the presence of the CD131-binding compound and IL-3. The level of TNFα secretion is then evaluated, for example, by ELISA.
[0234] In a further example, the CD131-binding compounds of this disclosure reduce or prevent IL-3-induced IL-13 release from human mast cells. For example, human cultured mast cells (e.g., 10-week-old peripheral blood-derived cells) are cultured in the presence of the CD131-binding compound and IL-3. The level of IL-13 secretion is then evaluated, for example, by ELISA.
[0235] In a further example, the CD131-binding compounds of this disclosure reduce or prevent the enhancement of IgE-mediated IL-8 release from human mast cells by IL-3 and / or IL-5 and / or GM-CSF. For example, cultured human mast cells (e.g., 10-week-old peripheral blood-derived cells) are cultured in the presence of the CD131-binding compound and IL-3 / IL-5 / GM-CSF (e.g., for about 48 hours). The cells are then cultured with IgE (e.g., human myeloma IgE) for a suitable time (e.g., about 24 hours), and IL-8 secretion is evaluated, for example, by ELISA.
[0236] In a further example, CD131-binding compounds reduce or prevent CFU-GM formation by CD34+ human bone marrow cells (or umbilical cord blood cells) cultured in the presence of SCF, GM-CSF, IL-3, and IL-5. For example, CD34+ cells (e.g., approximately 1 × 10⁻⁶) 3 Cells are cultured in the presence of a CD131-binding compound (e.g., on methylcellulose supplemented with bovine serum albumin, SCF, GM-CSF, IL-3, and IL-5 (e.g., 1% methylcellulose)). The cells are cultured for a suitable time (e.g., about 16 days), and the number of colonies formed thereafter is listed.
[0237] In further examples, CD131-binding compounds reduce the viability or induce death of immune cells (e.g., eosinophils) from sputum or nasal polyp tissue from subjects suffering from inflammatory airway disease or nasal polypopathy. For example, immune cells are cultured in the presence of IL-3 and / or IL-5 and / or GM-CSF and proteins or antibodies. Cell death is then assessed using standard methods, for example, by detecting annexin-V expression, or by using fluorescence-activated cell sorting.
[0238] In another example, CD131-binding compounds reduce or prevent IL-3-mediated histamine release from basophils. For example, low-density leukocytes containing basophils are incubated with IgE, IL-3, and antibody or antigen-binding fragments of varying concentrations. Control cells are free of immunoglobulin (positive control) or IL-3 (negative control). The levels of released histamine are then assessed using standard techniques, e.g., RIA. CD131-binding compounds can be considered to reduce the level of histamine release to a level lower than that of the positive control in order to neutralize IL-3 signaling. In one example, the level of reduction correlates with protein concentration. An exemplary method for assessing IL-3-mediated histamine release is described, for example, in Lopez et al., J. Cell. Physiol., 145:69, 1990.
[0239] Another assay for evaluating IL-3 signaling neutralization involves determining whether CD131-binding compounds reduce or prevent IL-3-mediated activity on endothelial cells. For example, human umbilical vein endothelial cells (HUVECs) are cultured in the presence of IL-3 (optionally, using IFN-γ) and various concentrations of CD131-binding compounds. The amount of secreted IL-6 is then evaluated, for example, using an enzyme-linked immunosorbent assay (ELISA). The control culture does not contain CD131-binding compounds (positive control) or IL-3 (negative control). CD131-binding compounds that reduce or prevent IL-6 production to levels below the positive control in the presence of IL-3 are considered to neutralize IL-3 signaling.
[0240] This disclosure envisions other methods for evaluating the neutralization of GM-CSF, IL-5, or IL-3 signaling.
[0241] Determining the effect pedal function As discussed herein, some CD131-binding compounds have reduced or enhanced effector function. Methods for evaluating ADCC activity are known in the art.
[0242] For example, the level of ADCC activity is, 51 Cr release assay, europium release assay, or 35 Evaluation is performed using S-release assays. In each of these assays, cells expressing CD131 are cultured with one or more of the listed compounds under conditions sufficient for the compounds to be taken up by the cells. 35 In the case of the S-release assay, cells expressing CD131 are selected. 35 S-labeled methionine and / or cysteine can be cultured for a sufficient time for the labeled amino acid to be incorporated into the newly synthesized protein. The cells are then cultured in or without the CD131-binding compound, and in the presence of immunoeffector cells, such as peripheral blood mononuclear cells (PBMCs) and / or NK cells. 51Cr, europium release assay, and / or 35 The amount of S release is then detected, and any little or no change in the presence of the CD131-binding compound compared to the absence of the CD131-binding compound indicates that the protein has reduced effector function and increased amount compared to the absence of the CD131-binding compound (or increased compared to the presence of the CD131-binding compound containing the IgG1 Fc region), exhibiting effector function or enhanced effector function. Exemplary publications disclosing assays for assessing the level of ADCC induced by the protein include Hellstrom, et al. Proc. Natl Acad. Sci. USA 83:7059-7063, 1986 and Bruggemann, et al., J. Exp. Med. 166:1351-1361, 1987.
[0243] Other assays for evaluating the level of protein-induced ADCC include the ACTI® non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc., CA, USA) or the CytoTox 96® non-radioactive cytotoxicity assay (Promega, WI, USA).
[0244] A C1q binding assay may be performed to confirm that the CD131-binding compound can bind to C1q and induce CDC. A CDC assay may also be performed to evaluate complement activation (see, for example, Gazzano-Santoro et al, J.Immunol.Methods 202:163, 1996).
[0245] Determination of half-life Some proteins encompassed by this disclosure have improved half-lives and are modified, for example, to extend their half-lives compared to unmodified proteins. Methods for determining proteins with improved half-lives will be obvious to those skilled in the art.
[0246] The half-life of the proteins disclosed herein can be measured, for example, by in vivo pharmacokinetic studies, according to the method described in Kim et al, Eur J of Immunol 24:542, 1994. According to this method, the radiolabeled protein is intravenously injected into mice, and its plasma concentration is measured periodically as a function of time, for example, from 3 minutes to 72 hours after injection. Alternatively, or additionally, other species, such as cynomolgus monkeys and humans, may be used, and / or unlabeled proteins may be injected and subsequently detected using enzyme-linked immunosorbent assay (ELISA). The clearance curve thus obtained should be biphasic, i.e., α-phase and β-phase. To determine the in vivo half-life of the protein, the clearance rate in the β-phase is calculated and compared to the clearance rate of the wild-type or unmodified protein.
[0247] The relative affinity of a protein to the embryonic Fc receptor (FcRn) can also indicate its relative in vivo half-life (see, for example, Kim et al, Eur J Immunol 24:2429, 1994).
[0248] Treatment effectiveness The therapeutic efficacy of compounds that bind to CD131 can be evaluated by comparing the severity of disease or symptoms in subjects treated with the compound to those not treated with the compound. Alternatively, or additionally, the therapeutic efficacy of candidate compounds can be evaluated in animal models. Preferred assays for evaluating therapeutic efficacy are described above in relation to determining neutralization by CD131-binding compounds.
[0249] In one example, the effectiveness of a protein for treating a condition is evaluated using an in vivo assay.
[0250] In one example, CD131-conjugated compounds are administered to non-human animals (e.g., non-human primates) and the number / level of immune cells (e.g., eosinophils) in circulation or in tissues or other samples (e.g., skin tissue from an inflamed site) is evaluated. CD131-conjugated compounds that reduce the number / level of immune cells compared to pre-administration and / or control mammals that have not received the protein are considered suitable for the treatment of diseases or conditions.
[0251] In one example, CD131-conjugated compounds are tested in a model of allergic contact dermatitis. In such a model, non-human mammals (e.g., rodents such as mice) are sensitized by applying 1-fluoro-2,4-dinitrobenzene (DNFB) to the epithelium of their abdomen. Subsequently, the mammals are stimulated (e.g., after 5 days) by applying DNFB to the epithelium of each side of their ears. The mammals are administered a CD131-conjugated compound, and the change in ear thickness from baseline (i.e., before administration) and / or the level of immune cells, e.g., neutrophils, mast cells, or T cells, at the site of inflammation are evaluated or estimated using standard techniques. CD131-conjugated compounds that reduce the change in ear thickness and / or the level of immune cells compared to control mammals that have not been administered the compound are considered suitable for the treatment of the disease or condition.
[0252] In another example, CD131-conjugated compounds were tested in a model of passive cutaneous anaphylaxis, where non-human mammals (e.g., rodents such as mice) sensitized to anti-dinitrophenyl (DNP)-IgE and subsequently stimulated with DNP-human serum albumin (HSA) were administered the CD131-conjugated compound, and changes in ear thickness and / or cytokine (TNF or IL-13) levels from baseline (i.e., before administration) were evaluated or estimated using standard techniques. CD131-conjugated compounds that reduce changes in ear thickness and / or cytokine levels compared to control mammals not administered the compound are considered suitable for the treatment of diseases or conditions.
[0253] In another example, levels of inflammatory cytokines such as IFNα or TNFα are detected in the circulation of mammals, for example, using ELISA. CD131-binding compounds that reduce cytokine levels compared to control mammals that have not been administered the compound are considered suitable for the treatment of diseases or conditions.
[0254] composition In some cases, the CD131-conjugated compounds described herein may be administered orally, parenterally, by inhalation spray, by adsorption, absorption, topically, rectally, nasally, orally, vaginally, intraventricularly, via a reservoir embedded in a conventional non-toxic, pharmaceutically acceptable carrier, or by any other convenient form of administration. As used herein, the term “parenterally” includes subcutaneous, intravenous, intramuscular, intraperitoneal, subarachnoid, intraventricular, intrasternal, polypyl, and intracranial injection or infusion techniques.
[0255] Methods for preparing CD131-conjugated compounds into a suitable form (e.g., a pharmaceutical composition) for administration to a target are known in the art, including, for example, the methods described in Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Co., Easton, Pa., 1990) and USPharmacopeia: National Formulary (Mack Publishing Company, Easton, Pa., 1984).
[0256] The pharmaceutical compositions of this disclosure are particularly useful for parenteral administration, such as intravenous administration, or administration into body cavities or tubules of organs or joints. The administration compositions generally comprise a solution of a CD131-conjugated compound dissolved in a pharmaceutically acceptable carrier, such as an aqueous carrier. Various aqueous carriers, such as buffered saline, can be used. The compositions may contain pharmaceutically acceptable auxiliary substances as needed to approximate physiological conditions, such as pH adjusters and buffers, and toxicity modifiers, such as sodium acetate, sodium chloride, potassium chloride, calcium chloride, and sodium lactate. The concentration of the CD131-conjugated compound of this disclosure in these formulations can vary widely and is mainly selected based on fluid volume, viscosity, body weight, etc., depending on the specific mode of administration and patient needs. Examples of carriers include water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Non-aqueous vehicles such as mixed oils and ethyl oleic acid may also be used. Liposomes may also be used as carriers. The vehicle may contain small amounts of additives, such as buffers and preservatives, to improve isotonicity and chemical stability.
[0257] In formulation, the CD131-conjugated compounds of this disclosure are administered in therapeutically / prophylactically effective amounts in a manner suitable for the drug formulation. The formulations are readily administered in various dosage forms, such as the injectable solutions described above, but other pharmaceutically acceptable forms, such as tablets, pills, capsules or other solids for oral administration, suppositories, pessaries, nasal solutions or sprays, aerosols, inhalants, and liposomes, are also intended. Pharmaceutical "sustained-release" capsules or compositions may also be used. Sustained-release formulations are generally designed to deliver a constant drug level over a long period of time and may be used to deliver the CD131-conjugated compounds of this disclosure.
[0258] Combination therapy For example, the CD131-conjugated compounds of this disclosure may be administered in combination with other compounds useful for treating the conditions described herein, as a concomitant or additional therapeutic step, or as an additional component of a therapeutic formulation.
[0259] For example, other compounds are anti-inflammatory compounds. Alternatively, or additionally, other compounds are immunosuppressants. Alternatively, or additionally, other compounds are corticosteroids such as prednisone and / or prednisolone. Alternatively, or additionally, other compounds are methotrexate. Alternatively, or additionally, other compounds are cyclophosphamide. Alternatively, or additionally, other compounds are mycophenolate mofetil. Alternatively, or additionally, other compounds are anti-CD20 antibodies (e.g., rituximab or ofatumumab). Alternatively, or additionally, other compounds are anti-CD22 antibodies (e.g., epratuzumab). Alternatively, or additionally, other compounds are anti-TNF antibodies (e.g., infliximab or adalimumab or golimumab) or soluble TNF receptors (e.g., etanercept). Alternatively, or additionally, other compounds include CTLA-4 antagonists (e.g., abatacept, CTLA4-Ig). Alternatively, or additionally, other compounds include anti-IL-6 antibodies. Alternatively, or additionally, other compounds include BLys antagonists, such as anti-BLys antibodies (e.g., belimumab).
[0260] This disclosure also provides a method for reducing the dose of corticosteroids required to treat subjects having an inflammatory skin condition, the method comprising co-administering a CD131-conjugated compound and a corticosteroid as described herein, wherein the corticosteroid is administered at a lower dose than when administered alone or in the absence of the CD131-conjugated compound. The CD131-conjugated compound and the corticosteroid do not need to be administered simultaneously only in a manner that has overlapping effects on the subject (e.g., both are simultaneously active in the subject).
[0261] In one example, the CD131-binding compound is administered concurrently with other therapies. In another example, the CD131-binding compound is administered before other therapies. In yet another example, the CD131-binding compound is administered after other therapies.
[0262] In some cases, CD131-binding compounds are administered in combination with cells. In some cases, the cells are stem cells, such as mesenchymal stem cells. In some cases, CD131-binding compound signaling is administered in combination with gene therapy.
[0263] Dosage and timing of administration The preferred dosage of the CD131-binding compounds of this disclosure varies depending on the specific CD131-binding compound, the condition to be treated, and / or the subject being treated. For example, determining a preferred dosage by starting with a suboptimal dosage and gradually increasing the dosage to determine an optimal or useful dosage is within the capabilities of a skilled physician. Alternatively, data from cell culture assays or animal studies may be used to determine an appropriate dosage for treatment / prevention, and the preferred dose may be determined by ED of the active compound with little or no toxicity. 50 It is within the range of circulating concentrations, including [specific component]. The dose may vary within this range depending on the form of administration used and the route of administration utilized. The therapeutic / prophylactic effective dose can first be estimated from a cell culture assay. The dose is determined in cell culture IC 50 The formulation may be used in animal models to achieve a circulating plasma concentration range that includes (i.e., the concentration or amount of the compound that achieves half of the maximum inhibition of symptoms). Using such information, a more accurate determination of a useful dose in humans can be made. Plasma levels can be measured, for example, by high-performance liquid chromatography.
[0264] In some examples, the methods of this disclosure include administering a prophylactic or therapeutically effective amount of the protein described herein.
[0265] The term "therapeutic dose" is defined as the amount administered to a subject in need of treatment that improves the subject's prognosis and / or condition, and / or reduces or inhibits one or more symptoms of the clinical condition described herein to a level below that observed and acceptable as a clinical diagnosis or clinical feature of that condition. The amount administered to the subject depends on specific characteristics of the condition being treated, such as general health, other diseases, age, sex, genotype, and weight, the type and stage of the condition being treated, the method of administration, and the characteristics of the subject. Those skilled in the art will be able to determine an appropriate dose in accordance with these and other factors. Therefore, this term is not limited to a specific amount, for example, the weight or quantity of protein, and this disclosure encompasses an amount of CD131-binding compound sufficient to achieve the results described in the subject.
[0266] As used herein, the term “preventive effective dose” is to mean an amount of protein sufficient to prevent, inhibit, or delay the onset of one or more detectable symptoms of a clinical condition. Those skilled in the art will recognize that such an amount varies, for example, depending on the specific C131-binding protein administered and / or the specific subject and / or the type or severity or level of the condition and / or predisposition to the condition (genetic or otherwise). Therefore, this term is not limited to a specific amount, for example, the weight or quantity of a CD131-binding compound, and the disclosure encompasses an amount of C131-binding protein sufficient to achieve the results described in the subject.
[0267] For in vivo administration of the CD131-binding compounds described herein, the usual dosage may be approximately 10 ng / kg to approximately 100 mg / kg or more of the solid's body weight per day. Depending on the severity of the disease or disorder being treated, repeated administration over several days or more may be maintained until the desired suppression of symptoms is achieved.
[0268] In some cases, the CD131 conjugate is administered at an initial (or loading) dose of approximately 1 mg / kg to approximately 30 mg / kg, for example, approximately 1 mg / kg to approximately 10 mg / kg, or approximately 1 mg / kg, 2 mg / kg, or 5 mg / kg. Subsequently, the CD131 conjugate may be administered at a low maintenance dose of approximately 0.01 mg / kg to approximately 2 mg / kg, for example, approximately 0.05 mg / kg to approximately 1 mg / kg, for example, approximately 0.1 mg / kg to approximately 1 mg / kg, for example, approximately 0.1 mg / kg, 0.5 mg / kg, or 1 mg / kg. The maintenance dose may be administered every 7 to 30 days, for example, every 10 to 15 days, for example, every 10, 11, 12, 13, 14, or 15 days.
[0269] In some cases, CD131-conjugated compounds may be administered in doses of approximately 0.01 mg / kg to approximately 50 mg / kg, for example, approximately 0.05 mg / kg to approximately 30 mg / kg, for example, approximately 0.1 mg / kg to approximately 20 mg / kg, for example, approximately 0.1 mg / kg to approximately 10 mg / kg, for example, approximately 0.1 mg / kg to approximately 2 mg / kg. For example, CD131-conjugated compounds may be administered in doses of approximately 0.01 mg / kg to approximately 5 mg / kg, for example, approximately 0.1 mg / kg to approximately 2 mg / kg, for example, approximately 0.2 mg / kg or 0.3 mg / kg or 0.5 mg / kg or 1 mg / kg or 1.5 mg / kg (e.g., without a higher loading dose or a lower maintenance dose). In some cases, multiple doses are administered, for example, every 7 to 30 days, every 10 to 22 days, every 10 to 15 days, or every 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 days. For example, the CD131 conjugate is administered every 7 days, or every 14 days, or every 21 days.
[0270] In some cases, at the start of treatment, mammals are administered a CD131-binding compound for a continuous period of up to 7 days, or up to 6 days, or up to 5 days, or up to 4 days.
[0271] In mammals that do not respond adequately to treatment, the drug may be administered multiple times per week. Alternatively, or in addition, increased doses may be administered.
[0272] In another example, in mammals experiencing adverse reactions, the initial (or loading) dose may be divided over several days a week or over a number of consecutive days.
[0273] The administration of the CD131-conjugated compound by the method of this disclosure may be continuous or intermittent, depending, for example, the physiological state of the recipient, whether the purpose of administration is therapeutic or prophylactic, and other factors known to those skilled in the art. The administration of the CD131-conjugated compound may be essentially continuous over a pre-selected period, or it may be a series of intervald doses, for example, either during or after the onset of the condition.
[0274] kit Another example of this disclosure provides a kit containing compounds useful for treating or preventing the inflammatory skin conditions described above.
[0275] For example, the kit includes (a) a container containing the compounds described herein in an optionally pharmaceutically acceptable carrier or diluent, and (b) a package insert containing instructions for treating, preventing, or reducing the effects of an inflammatory skin condition in a subject.
[0276] According to this example of the present disclosure, the accompanying information is indicated on the container or attached to the container. Suitable containers include, for example, bottles, vials, syringes, etc. Containers may be formed from a variety of materials, such as glass or plastic. The container holds or contains a composition that is effective for the treatment or prevention of inflammatory skin conditions and may have a sterile access port (for example, the container may be an intravenous solution bag or vial with a stopper that can be pierced by a subcutaneous needle). At least one activator in the composition is a compound that binds to CD131. The label or accompanying information indicates that the composition is administered to a subject of treatment, e.g., a subject who has or is at risk of developing an inflammatory skin condition, and that specific guidance regarding the dosage and interval of the compound and any other pharmaceuticals is provided. The kit may further include additional containers containing pharmaceutically acceptable diluent buffers, e.g., bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and / or dextrose solution. The kit may further include other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0277] This disclosure includes the following non-limiting embodiments. [Examples]
[0278] Example 1: Materials and Method antibody CSL311(ahu9A2-G4pK-VR24-29) is a humanized antibody that targets the common cytokine binding site (site 2) of the human βc(CD131) homodimer. The heavy chain amino acid sequence is provided in SEQ ID NO: 14, and the light chain amino acid sequence is provided in SEQ ID NO: 15. A human IgG4 isotype control antibody (e.g., chBM4-G4pK) was used for comparison.
[0279] ACD (Contact Hypersensitivity) Model Wild-type (WT) mouse, βc knockout (βc - / - / β IL-3 - / -) Mice, and (i) human βc receptor transgene, and (ii) knockout of both endogenous β subunits (βc - / - / β IL-3 - / - Homozygous transgenic mice (referred to as "hβcTg") were used. The mouse colonies were housed at Animal Care Facility, UniSA CRI, Building HB (Adelaide, Australia). Mice aged 16–28 weeks were used in experiments conducted in accordance with the ethical guidelines of the National Council for Health and Medical Research of Australia and with the approval of the Animal Ethics Committee of the University of South Australia (Animal Ethics Approval Number U21 / 17 / ).
[0280] First, the mouse was anesthetized, and approximately 3 cm of the posterior ventral side was shaved with an electric shaver. 2 Area. Using a pipette, 30 μl of 0.5% 1-fluoro-2,4-dinitrobenzene (DNFB) solution was applied to the epithelium of the abdomen of mice. Mice were restrained for 5-10 seconds to allow the solution to dry. Five days after allergen sensitization, baseline auricle thickness of both ears was measured using a dial thickness gauge (model G-1A; Ozaki MFG.Co.,Ltd). Immediately after measurement, 10 μl of 0.2% DNFB solution was applied to both sides of the right auricle (20 μl total). Alternatively, 10 μl of 100% acetone (vehicle) was applied to both sides of the left auricle (20 μl total). 24 hours after induction, auricle thickness was measured at 24-hour intervals for 12 days. The change in auricle thickness (Δ ear swelling, mm) was calculated using the following formula: (daily ear thickness after induction) - (baseline ear thickness). CSL311 or its isotype mAb (10 mg / kg) was intravenously injected into the tail vein of hβcTg mice on days 1, 3, and 5 after induction (a total of three injections). The mice were euthanized at the end of the experiment, and both ears and lymph nodes were collected for further analysis.
[0281] Histology - Tissue Treatment Ear skin samples treated with DNFB and vehicle were histologically examined. The tissue samples were fixed in 10% buffered formalin, processed, embedded in paraffin, and cut into 4 μm sections. For dewaxing and hydration, the tissue sections were sequentially placed in xylene (5 min x 2), 100% ethanol (4 min x 2), 70% ethanol (4 min), and 50% ethanol (4 min), and then washed with deionized water.
[0282] Toluidine blue staining Dewaxed tissue sections were stained with 0.2% toluidine blue (pH 1.0, Sigma-Aldrich) at room temperature for 90 seconds, then rinsed with tap water. The sections were dehydrated with xylene and mounted on DPX mounting medium. Images of the ear sections were taken using a Hamamatsu nanozoomer (40x magnification, Adelaide Microscopy Facility) and exported using NDP View software (v2). The total area of the polyp (mm²) was measured. 2 Mast cells (indicated by purple cytoplasmic granules) per unit area were evaluated using Fuji Image J software (1.50e, National Institutes of Health).
[0283] Hematoxylin and eosin staining Dewaxed tissue sections were stained with hematoxylin for 3 minutes, then washed with running tap water for 5 minutes. The sections were differentiated in 1% acid ethanol (1% HCl in 70% ethanol) for 5 minutes, washed with running tap water, and then stained in 1% eosin Y solution for 10 minutes. After washing the sections with tap water for 5 minutes, they were dehydrated with xylene and mounted on DPX mounting medium. Images of the ear sections were taken using a Hamamatsu Nanozoomer (40x magnification, Adelaide Microscopy Facility) and exported using NDP View software (v2).
[0284] Flow cytometry analysis of ear tissue Ear tissue was divided into dorsal and ventral sections and digested in dispase II solution (final concentration 2 U / ml) in RPMI1640 medium at 37°C for 60 minutes. The dermis was then separated from the epidermis using forceps, and the tissue was cut into small pieces with scissors. These were then incubated in RPMI1640 medium at 37°C for 60 minutes with collagenase IV (final concentration 0.2 mg / mL) and DNase I (final concentration 0.05 mg / mL). The digested tissue was passed through a 70 μm nylon cell strainer (Falcon) to obtain a single-cell suspension. The cells were washed in FACS buffer (PBS with 2% FBS) and incubated for 15 minutes with Live / Dead Aqua staining (1 / 1000 dilution, Molecular Probe) and anti-mouse CD16 / CD32 antibody (eBioscience). To detect mouse T cell subsets, cells were incubated for 30 minutes on ice with rat anti-mouse Ly6C and Ly6G(Gr-1)PE (BD Biosciences, RB6-8C5, 1:200 dilution) and rat anti-mouse F4 / 80APC (eBiosciences, BM8, 1:200 dilution). Data were obtained as described above.
[0285] statistical analysis For normally distributed data, we compared different groups using independent t-tests and performed multiple comparisons using two-way ANOVA with Bonferroni post-hoc tests. GraphPad Prism Version 5.0d was used. The asterisks above the groups indicate the level of significance of that group compared to the control: *p<0.05; **p<0.01; ***p<0.001.
[0286] MC-903-induced atopic dermatitis model Mixed-sex mice aged 8-9 weeks were used in this study. Baseline auricle thickness of both ears was measured on day 0 using a dial thickness gauge, followed by subcutaneous treatment with 20 μl of 100% ethanol or 20 μl of 2 nM MC-903 dissolved in 100% ethanol for 9 days. Auricle thickness was measured at 24-hour intervals for 10 days. The change in auricle thickness (Δ ear swelling, mm) was calculated using the following formula: (daily ear thickness after induction) - (baseline ear thickness). CSL311 or isotyped mAb (10 mg / kg) was intravenously injected into the tail vein of hβcTg mice on days 1, 3, and 5 (a total of 3 injections). Mice were euthanized at the end of the experiment.
[0287] Example 2: CSL311 reduces cellular inflammation and histopathology in an hβcTg mouse model of contact dermatitis. To establish the therapeutic potential of CSL311 for the treatment of ACD, contact hypersensitivity reactions to hapten, 2,4-dinitrofluorobenzene (DNFB), applied to epithelium were investigated. WT, βc - / - / β IL-3 - / - WT mice and hβcTg mice were first sensitized by applying DNFB to their shaved abdomens. Five days later, DNFB was applied to the right ear, and a vehicle control was applied to the left ear of each mouse. Changes in ear thickness (swelling) were measured daily for 12 days, and on day 12, cellular inflammation, tissue visualization, and epithelial thickness were measured. WT mice showed a substantial increase in ear thickness, peaking at days 7-8 and then subsiding. However, βc mice that were unresponsive to any βc cytokines... - / - / β IL-3 - / - In mice treated with DNFB, the magnitude of the ear swelling response was significantly reduced (Figure 1). Application of the vehicle control did not induce an inflammatory response in DNFB-sensitized mice.
[0288] CSL311 or isotype control antibody (10 mg / kg) was intravenously injected into hβcTg mice 24 hours after the second DNFB challenge, and then administered every other day until day 5 (a total of 3 injections). Mice treated with the isotype control antibody exhibited an ear swelling response similar to that of WT mice (Figure 1). In contrast, treatment of hβcTg mice with CSL311 resulted in ear swelling similar to that of βcTg mice. - / - / β IL-3 - / - The levels were significantly reduced to a level similar to that of mice (Figure 1). No differences were observed in the vehicle-treated ear or skin of the sensitized site between isotype control and CSL311-treated hβcTg mice. DNFB-treated ears of both WT mice and isotype control antibody-treated hβcTg mice were characterized by substantial cutaneous edema, cell infiltration, keratosis, and epithelial hypertrophy. These features were observed in βc treated with CSL311. - / - / β IL-3 - / - It was almost absent in the DNFB-treated ears of both mouse and hβcTg mice (Figure 2). These data suggest that blocking βc cytokine signaling is an effective treatment for ACD in this model.
[0289] CD8 was found in the ear tissue of DNFB-treated WT mice compared to non-DNFB-treated WT mice, both at the peak of the response (day 6) (Figures 6-9) and during the recovery phase of the response (day 12) (Figures 3-5). + A significant increase in T cells, mast cells, neutrophils, eosinophils, and macrophages was detected. βc - / - / β IL-3 - / -The absence of βc cytokine signaling in mice reduced the infiltration of all cell types except macrophages in DNFB-treated ears. Analysis of ear tissue from hβcTg mice treated with isotype control antibodies revealed a significant increase in CD8+ T cells, mast cells, neutrophils, and eosinophils in DNFB-treated ears at both day 6 (Figures 6-9) and day 12 (Figures 3-5), similar to WT mice. Treatment of hβcTg mice with CSL311 eliminated the accumulation of CD8+ T cells (Figure 6), neutrophils (Figure 7), eosinophils (Figure 8), and mast cells (Figure 9) in ear tissue at day 6 after DNFB treatment, as well as the reduced mast cells (Figure 3), neutrophils (Figure 4), and eosinophils (Figure 5) at day 12. Therefore, these data indicate that blocking GM-CSF and IL-5 signaling by CSL311 limits immune cell accumulation at allergen exposure sites and effectively reduces pathology in this hβcTg model of ACD.
[0290] The effect of CSL311 is likely mediated by the blockade of either GM-CSF or IL-5, since hβcTg mice do not respond to IL-3. Furthermore, these data suggest that CSL311 is mediated by βc - / - / β IL-3 - / - Because ear swelling can be reduced to a level comparable to that in mice, this ACD model demonstrates that βc cytokine-driven ear swelling is completely dependent on GM-CSF and / or IL-5 (Figure 1). To definitively determine whether IL-3 contributes to the contact hypersensitivity response in this model, IL-3 - / - Changes in ear thickness in mice were measured using the same model described above. WT and IL-3 - / - No differences in ear swelling response or mast cell infiltration were observed between this model and mice, indicating that GM-CSF and IL-5 are major regulators of ACD in this model.
[0291] Example 3: CSL311 reduces inflammation in an hβcTg mouse model of atopic dermatitis. The efficacy of CSL311 treatment was investigated in a well-characterized atopic dermatitis (AD) model. In this model (described in Example 1), skin inflammation was induced using daily application of the vitamin D3 analog MC903 (also known as calcipotriol). The resulting phenotype included epidermal thickening, skin hyperplasia, and an increase in inflammatory cells in the skin, particularly mast cells, eosinophils, basophils, and T helper type 2 cells.
[0292] Administration of CSL311 to hβcTg mice in this MC903-induced atopic dermatitis model significantly reduced ear skin thickening (Figure 10).
Claims
1. A pharmaceutical composition for treating an inflammatory skin condition in a subject, comprising a compound that binds to CD131 and neutralizes signaling by granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin (IL) 5.
2. (i) the inflammatory skin condition is hypersensitivity, and / or (ii) The pharmaceutical composition of claim 1, wherein the inflammatory skin condition is contact dermatitis or atopic dermatitis.
3. (i) the hypersensitivity is type IV hypersensitivity, and / or (ii) The pharmaceutical composition according to claim 2, wherein the contact dermatitis is allergic contact dermatitis.
4. administering said compound that binds to CD131 and neutralizes signaling by GM-CSF and IL-5; a) reducing swelling at the site of inflammation; and / or b) reducing mast cell infiltration at the site of inflammation; and / or c) reducing neutrophil infiltration at the site of inflammation; and / or d) reducing CD8+ T cell infiltration at the site of inflammation; and / or The pharmaceutical composition according to claim 1 or 2, wherein e) it reduces neutrophil infiltration at the inflammatory site.
5. 3. The pharmaceutical composition of claim 1 or 2, wherein the compound that binds to CD131 and neutralizes signaling by GM-CSF and IL-5 also neutralizes signaling by IL-3.
6. The compound that binds to CD131 and neutralizes signaling by GM-CSF and IL-5 is a) inhibiting GM-CSF-induced proliferation of TF-1 cells with an IC50 of at least 100 nM; and / or b) inhibiting IL-5-induced proliferation of TF-1 cells with an IC50 of at least 100 nM; and / or c) inhibiting IL-3-induced proliferation of TF-1 cells with an IC50 of at least 100 nM.
7. The pharmaceutical composition according to claim 1 or 2, wherein the compound that binds to CD131 and neutralizes signal transduction by GM-CSF and IL-5 is a protein that comprises an antigen-binding site that binds to CD131.
8. The pharmaceutical composition of claim 7, wherein the KD of the protein for a polypeptide comprising the sequence set forth in SEQ ID NO:5 is about 10 nM or less when the polypeptide is immobilized on a solid surface and the KD is determined by surface plasmon resonance.
9. 3. The pharmaceutical composition of claim 1, wherein the compound that binds to CD131 and neutralizes signaling by GM-CSF and IL-5 is a protein comprising an Fv.
10. The protein is (i) single chain Fv fragment (scFv), (ii) a dimeric scFv (di-scFv), or (iii) diabodies, (iv) triabodies, (v) tetrabodies, (vi) Fab, (vii) F(ab')2, (viii) Fv, (ix) one of (i)-(viii) linked to the constant region of an antibody, Fc, or heavy chain constant domain (CH)2 and / or CH3; (x) one of (i) to (viii) linked to albumin or a functional fragment or variant thereof, or a protein that binds albumin; or The pharmaceutical composition of claim 9, comprising: (xi) an antibody.
11. The pharmaceutical composition of claim 7, wherein the protein is a single domain antibody (sdAb).
12. The pharmaceutical composition of claim 7, wherein the protein comprises an antibody variable region that binds to CD131 and competitively inhibits the binding of antibody 9A2-VR24.29, the antibody comprising a VH comprising the sequence set forth in SEQ ID NO:6 and a VL comprising the sequence set forth in SEQ ID NO:18, to CD131.
13. The antigen-binding site is (i) to an epitope within site 2 of CD131, and / or (ii) to an epitope upon dimerization of two CD131 polypeptides, and / or The pharmaceutical composition of claim 7, which (iii) binds to a residue within domain 1 of a CD131 polypeptide and a residue within domain 4 of another CD131 polypeptide.
14. The pharmaceutical composition of claim 13, wherein the residues within domain 1 of CD131 include residues within the region 101-107 of SEQ ID NO:1 and / or the residues within domain 4 of CD131 include residues within the region 364-367 of SEQ ID NO:
1.
15. The protein is (i) an antibody variable region comprising a VH comprising three CDRs of the VH comprising the amino acid sequence set forth in SEQ ID NO: 6, and a VL comprising three CDRs of the VL comprising the amino acid sequence set forth in SEQ ID NO: 18; and / or (ii) a VH comprising the amino acid sequence set forth in SEQ ID NO: 6 and a VL comprising the amino acid sequence set forth in SEQ ID NO: 18; and / or (iii) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 14, and a light chain comprising the amino acid sequence set forth in SEQ ID NO:
15. The pharmaceutical composition of claim 7,
